WO1999047497A2 - Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment - Google Patents

Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment Download PDF

Info

Publication number
WO1999047497A2
WO1999047497A2 PCT/CA1999/000212 CA9900212W WO9947497A2 WO 1999047497 A2 WO1999047497 A2 WO 1999047497A2 CA 9900212 W CA9900212 W CA 9900212W WO 9947497 A2 WO9947497 A2 WO 9947497A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
independently
compound
het
group
Prior art date
Application number
PCT/CA1999/000212
Other languages
French (fr)
Other versions
WO1999047497A3 (en
Inventor
Yves Gareau
Marc Labelle
Helene Juteau
Michel Gallant
Nicolas Lachance
Michel Belley
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815856.1A external-priority patent/GB9815856D0/en
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Priority to CA002322742A priority Critical patent/CA2322742A1/en
Priority to JP2000536694A priority patent/JP2002506851A/en
Priority to AU27086/99A priority patent/AU756333B2/en
Priority to EP99907214A priority patent/EP1071648A2/en
Publication of WO1999047497A2 publication Critical patent/WO1999047497A2/en
Publication of WO1999047497A3 publication Critical patent/WO1999047497A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to compounds which are useful for treating or preventing prostaglandin mediated diseases, methods of treatment and pharmaceutical compositions containing such compounds.
  • the compounds are structurally different from conventional NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.
  • PGE2 Prostaglandin E2
  • prostaglandin ligands, agonists or antagonists depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties, and in addition inhibit hormone-induced uterine contractions. Moreover, the compounds have anti-cancer effects.
  • the compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
  • the present invention relates to compounds represented by formula I:
  • HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(0)n and N(0) m wherein m is 0 or 1 and n is 0, 1 or 2;
  • Z is OH or NHSO 2 R 19 ;
  • R 1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R a )4_9 , -
  • each R 4 is independently H, F, CF 3 or lower alkyl, or two R 4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0) m ; each R 5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF 3 , lower alkyl-HET, lower alkenyl-HET or -(C(R 18 ) 2
  • each R 12 is independently H, lower alkyl or benzyl; each R 13 is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R b ) 2 , C0 2 R 12 , CN, CF 3 or NO 2 > R 14 and Rl5 are independently lower alkyl, halogen, CF 3 ,
  • each R 16 is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF 3 .
  • each R 17 is independently H, lower alkyl or Bn;
  • each R 18 is independently H, F or lower alkyl, and when two
  • R 18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0) n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF 3 '
  • each R 20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF 3 or Ph(R 13 ) 2 and each Ra is independently selected from the group consisting of:
  • a method of treating or preventing a prostaglandin mediated disease is also included which is comprised of administering to a mammalian patient in need thereof, a compound of formula I in an amount which is effective for treating or preventing a prostaglandin mediated disease.
  • the present invention relates to carboxylic acids and acylsulfonamides, which are ligands at prostaglandin receptors, as well as a method for treating or preventing a prostaglandin mediated disease comprising administering to a patient in need of such a treatment of an amount of compound of Formula I which is effective for treating or preventing a prostaglandin mediated disease.
  • HET represents a 5-12 membered aromatic ring system containing 0-3 heteroatoms selected from O, S(O) n and N wherein n is 0,
  • HET may be substituted with up to three substituents on the aromatic ring system, Rl, R2 and R3.
  • "Aromatic ring systems" as used herein includes aryl and heteroaryl groups such as benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.
  • HET2 is a subset of HET and represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.
  • Aryl refers to aromatic 6-10 membered groups having 1-2 rings and alternating (resonating) double bonds. Examples include phenyl, biphenyl and naphthyl.
  • Heteroaryl refers to aromatic 5-12 membered groups having alternating (resonating) double bonds and containing from 1-4 heteroatoms selected from O, S(0) n and N. Examples include the following: : quinoline, furan, benzofuran, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, oxazole, indole, isoindole, pyridine, isoquinoline, imidazole, thiazole, triazole, 1,3- methylene dioxobenzene, pyrrole and naphthyridine,
  • Heterocyclyl refers to non- aromatic 5-12 membered cyclic groups having 1-4 heteroatoms selected from O, S(0) n and N.
  • heterocyclic groups are piperidine, piperazine, pyrrolidine, tetrahydrofuran, tetrahydropyran and morpholine.
  • X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0) n and N(0) m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group X in positions which are ortho relative to each other.
  • Examples are selected from the group consisting of: phenyl, naphthyl, biphenyl, quinoline, furan, benzofuran, pyridyl, pyrrole, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5- thiadiazole, triazole, 1,2-methylenedioxybenzene, thienopyridine, oxazole and indole.
  • alkyl, alkenyl, and alkynyl mean linear, branched, and cyclic structures and combinations thereof.
  • “Lower alkyl” means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, s- and t-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, and the like. When propyl and butyl are recited without the isomeric form being specified, these include all isomers thereof. "Lower alkenyl” means alkenyl groups of 2 to 7 carbon atoms.
  • lower alkenyl groups examples include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2- methyl-2-butenyl, cyclopropen-1-yl, cyclohexen-3-yl and the like. When cis or trans is not specified, both are intended in pure form as well as in the form of a mixture of isomers.
  • Lower alkynyl means alkynyl groups of 2 to 7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3- methyl-1-pentynyl, 2-heptynyl, 2-(cyclopropyl)ethenyl, 3-(cyclobutyl)-l- propynyl and the like.
  • Halogen (halo) includes F, Cl, Br and I.
  • AIBN 2.2'-azobisisobutyronitrile
  • CC1 4 carbon tetrachloride
  • DIBAL diisobutyl aluminum hydride
  • LDA lithium diisopropylamide m-CPBA metachloroperbenzoic acid
  • NBS N-bromosuccinimide
  • NSAID non-steroidal anti-inflammatory drug
  • PCC pyridinium chlorochromate
  • Ph phenyl
  • c-Bu cyclobutyl
  • c-Pen cyclopentyl
  • c-Hex cyclohexyl
  • -N(R ) 2 represents -NHH, -NHCH , -
  • the invention relates to a compound represented by formula I:
  • HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O) n and N(0)m wherein m is 0 or 1 and n is 0, 1 or 2;
  • X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0) n and N(0)m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;
  • Z is OH or NHS0 2 R 19 ;
  • R 1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R a )4_9 , - (C(R 4 )2)pSR5, -(C(R 4 ) 2 ) p OR 8 , -(C(R 4 ) 2 ) p N(R 6 ) 2 , CN, N0 2 , -(C(R 4 ) 2 ) p C(R 7 ) 3 , -
  • each R 4 is independently H, F, CF 3 or lower alkyl, or two R 4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0) m ;
  • each R 5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF 3 , lower alkyl-HET, lower alkenyl-HET or -(C(R 18 ) 2 ) p Ph(R ⁇ ) ⁇ -
  • each R 6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF 3 , Ph, Bn and when two R 6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0) n or N(O) m ;
  • each R 7 is independently H, F, CF 3 or lower alkyl, and when two R 7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(0) n and N(O) m ;
  • each R represents H or R5;
  • each R 9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn;
  • each R 10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF 3 , Ph(R n ) ⁇ -3, CH 2 Ph(R
  • R 14 and Rl5 are independently lower alkyl, halogen, CF 3 , OR 16 , S(0) n R 16 or C(R 16 ) 2 OR 17 ; each R 16 is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF 3 .
  • each R 17 is independently H, lower alkyl or Bn;
  • each R 18 is independently H, F or lower alkyl, and when two R 18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0) n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF 3 >
  • each R 20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF 3 or Ph(R 13 ) 2 and each Ra is independently selected from the group consisting of: H, OH, halo, CN, NO2, amino, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkylamino, di-Ci- 6alkylamino, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(O) Ct ⁇ - ⁇ alkynyl, CO2H, C ⁇ 2Ci-6alkyl, C ⁇ 2C2-6alkenyl, and C ⁇ 2C2-6alkynyl, said alkyl, al
  • HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O) n and N(0) wherein m is 0 or 1 and n is 0, 1 or 2;
  • X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0) n and N(0) m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other;
  • Z is OH or NHSO 2 R 19 ;
  • R 1 R and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(R a )4_9 .
  • each R 4 is independently H, F, CF 3 or lower alkyl, or two R 4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0) m ; each R 5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF 3 , lower alkyl-HET, lower alkenyl-HET or -(C(R 18 ) 2
  • each R 12 is independently H, lower alkyl or benzyl; each R is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R 6 ) 2 , CO 2 R 12 , CN, CF 3 or NO 2 >
  • R 14 and Rl5 are independently lower alkyl, halogen, CF 3 , OR 16 , S(0) n R 16 or C(R 16 ) 2 OR 17 ; each R 16 is independently H, lower alkyl, lower alkenyl, Ph, Bn, CHF2 or CF 3 .
  • each R 17 is independently H, lower alkyl or Bn; each R 18 is independently H, F or lower alkyl, and when two R 18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(O)n or N; each R 19 is lower alkyl, lower alkenyl, lower alkynyl, CF 3 , HET2(Ra)4_ 9 , lower alkyl-HET2(Ra) 4 _ 9 0 r lower alkenyl-HET2(Ra) 4 _ 9 , wherein HET2 represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl; each R 20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF 2 , CF 3 or Ph(R 13 ) 2
  • HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.
  • HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine,
  • an embodiment of the present invention is represented by formula I wherein HET is selected from the group consisting of: benzene, biphenyl, naphthylene, indole, thiophene, benzofuran and quinoline.
  • HET is selected from the group consisting of: benzene, biphenyl, naphthylene, indole, thiophene, benzofuran and quinoline.
  • A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO2, CH2, -C(O)- , -OCH2-, -CHOH- , -C(OH)(CH3)- and -CH 2 -0- .
  • A is selected from the group consisting of: : S, S(O), SO2, CH2, -C(O)-.
  • all other variables are as originally described with respect to formula I.
  • Another embodiment of the present invention that is of particular interest is represented by formula I wherein X represents phenyl optionally substituted with R 14 and R 15 .
  • X represents phenyl and R 14 and R 15 are absent or represent halo.
  • all other variables are as originally described with respect to formula I.
  • Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is NHS0 2 R 19 .
  • Z is NHS0 2 R 19 and R 19 represents a member selected from the group consisting of: lower alkyl and HET(Ra)3.
  • HET is selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.
  • HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole;
  • A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO2, CH2, -C(O)- , -OCH2- , -CHOH- , - C(OH)(CH3 )- and -CH2-O-;
  • X represents phenyl optionally substituted with R 14 and R 15 ;
  • Z is NHS0 2 R 19 and
  • R 19 represents a member selected from the group consisting of: lower alkyl and HET(Ra) 3 .
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
  • compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of Formula I and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for oral administration to humans may contain from about 0.5 mg to about 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
  • compound I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • the compound of the invention is effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, solutions, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water-miscible solvents such as propylene glycol, PEGs and ethanol
  • an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally- occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • colouring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavouring agents such as sucrose, saccharin or aspartame.
  • sweetening agents such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
  • the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Compound I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
  • a pharmaceutical carrier cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
  • prostaglandins This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent or ameliorate prostaglandin mediated diseases and conditions in mammals and especially in humans: Pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases.
  • Such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
  • Compound I may also be of use in the treatment and/or prevention prostaglandin-mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis.
  • Compound I will also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders.
  • compound I By virtue of its prostanoid or prostanoid antagonist activity, compound I will prove useful as an alternative to NSAID'S particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; thrombosis, occlusive vascular diseases; those prior to surgery or taking anti-coagulants.
  • Compound I will also be useful as a cytoprotective agent for patients under chemotherapy.
  • the invention encompasses pharmaceutical compositions for treating prostaglandin E 2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a COX-2 selective NSAID; a conventional NSAID; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydro
  • the invention encompasses a method of treating prostaglandin E 2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
  • Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius.
  • Boronic acids and esters can be prepared from the corresponding halide according to literature procedure and reference cited therein (Charette, A.B.; Giroux, A. J. Org. Chem. 1996, 61, 8718; Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 1995, 60, 7508; Miyaura, N.; Suzuki, A. Chem. Rev, 1995, 95, 2457; Murata, M.; Watanabe, S.; Masuda, Y. J. Org. Chem. 1997, 62, 6458; Watanabe, T. Miyaura, N.; Suzuki, A.
  • Cinnamic ester 1 is treated with a brominating agent such as NBS in a refluxing inert solvent such as CC1 4 , with the use of an initiator like benzoyl peroxide or light.
  • a brominating agent such as NBS
  • a refluxing inert solvent such as CC1 4
  • an initiator like benzoyl peroxide or light.
  • the resulting benzylic bromide is reacted in a Suzuki coupling reaction with the appropriate boronic acid or ester, a catalyst such as tetrakis(triphenylphosphine) palladium and cesium fluoride or Na 2 C0 3 or a base in an inert refluxing solvent such as DME at 80-90° C.
  • the new cinnamic ester 3 is hydrolyzed with aqueous sodium hydroxide to afford the acid 4 that is converted to the cinnamic sulfonamide 5 with a coupling reagent such as DCC or DCI in CH 2 C1 2 at r.t.
  • Cinnamic ester 2 is treated with an aryl or heteroaryl mercaptan, alcohol or amine, and with a base such as a hydride or an amine in benzene or THF at 0-23° C.
  • the cinnamic ester 8 is converted to 9 according to Method A.
  • the aldehyde 11 is prepared by an addition-elimination of a mercapto, hydroxy or amino aryl or heteroaryl with a base such as I ⁇ CO g in refluxing CHC1 3 . If needed a higher boiling point solvent can be used. This type of rection can also be performed with CuO in DMF.
  • An Emmons-Horner type reaction or Wittig in toluene at r.t. followed by Method A (or oxidation as described in Method B) results in the cinnamic sulfonamide 13.
  • Acetal 14 that came from an acetalization from a suitably substituted bromo benzaldehyde is converted to the Grignard reagent with magnesium in an etheral solvent at reflux and quenched with an aryl or heteroaryl ketone.
  • the alcohol 16 is reacted with an halide and a base (or protected as the o-nitrobenzyl, and removed at the end of the sequence) to furnish the compound 17.
  • Deprotection of the acetal under standard conditions followed by Method C gives 18.
  • Alcohol 16 is converted to an acetate with acetyl chloride (or acetic anhydride and an amine base) and coupled with a Grignard reagent and a copper salt at low temperature.
  • the alcohol 16 could also be converted to the bromide and treated in a similar way to yield 20.
  • Compound 20 is then converted to the cinnamic sulfonamide 21 according to Method D.
  • 22 can be treated with A1(R 7 ) 3 in toluene at 80 °C for 24h and 23 converted to the aldehyde with n-BuLi/DMF followed by an Emmons-Horner reaction and Method A to yield compound 21.
  • a suitably substituted bromo toluene 24 is treated with n- Buli at low temperature and quenched with an aryl or heteroaryl aldehyde.
  • the resulting alcohol is oxidized to the ketone with PDC, PCC, Mn0 2 or other typical oxidizing agent.
  • the carbonyl is treated with SF 4 , MoF 6 -BF 3 (or converted to a thioacetal and treated with nitrosonium BF 4 - pyridinium*HF) to yield the difluoride.
  • the appropriately substituted methyl bromo(or triflate) benzoate 27 is converted to compound 28 by a Suzuki coupling reaction followed by hydrogenation.
  • a Stille coupling reaction could also be used.
  • Benzylic bromination or benzylic oxidation followed by treatment with a brominating agent such as CBr 4 /triphenylphosphine gives compound 29 which can be treated with a boronic acid, or a tin compound (Stille) to furnish compound 30.
  • Reduction of the ester with DIBAL, oxidation with Mn0 2 and Method C gives compound 31.
  • the halide 29 can also be converted the Grignard reagent and added to the ketone. Dehydration under acidic conditions results in compound 32. Reduction of the double bond under standard conditions, followed by Methods G and C gives compound 33. From compound 32, cyclopropanation with diazomethane and palladium (0) followed by Methods G, C and A gives compound 34.
  • the (heterocyclic) vinylic bromide 35 is reacted in a Suzuki coupling reaction with an aryl or hetero aryl boronic acid and converted to a new borane by 9-BBN addition followed by a second Suzuki reaction with compound 14.
  • Compound 37 thus formed is reduced by hydrogenolysis ( H ⁇ metal or diimide) and deprotection followed by Method C gives cinnamic sulfonamide 39.
  • Ketone 40 which comes from oxidation of the corresponding alcohol is reacted with a phosphonium salt or phosphono ester with a base such as LDA to give the cinnamic ester 41.
  • Method A yields 42 and reduction of the double bond by the previously mentioned method gives the acyl sulfonamide 43.
  • Cinnamic ester 3 is reduced to 44 by the previously mentioned method, ⁇ Alkylation with a base such as LDA followed by an alkylating agent results in 45 after conversion to the acyl sulfonamide.
  • Cinnamic ester 3 is reduced to 46 with DIBAL and the double bond converted to a cyclopropane by a Simmons-Smith reaction, or similar reactions recently described in the literature.
  • Compound 47 is then oxidized and the cinnamic sulfonamide 48 is prepared according to Method A.
  • Ester 49 which can come from the homologation of the appropriately substituted methyl ortho-toluate, is treated with a base and with an alkylating agent to furnish compound 50. Benzylic bromination and Suzuki coupling gives an intermediate ester. Homologation according to J. Amer. Chem. Soc; 1985, 1429; J. Org. Chem. 1992, 7194, followed by alkylation with a base such as LDA and an alkylating agent furnishes acylsulfonamide 51 by Method A.
  • Compound 50 can also be converted to the benzylic bromide and to compound 52 by Method A.
  • Suitably substituted compound 53 is treated with a boronic acid to give compound 54 which is reduced with LDA to the alcohol 55.
  • Treatment with phosgene followed with the appropriate sulfonamide gives compound 56.
  • This can also be prepared by mixing phosgene and the sulfonamide at 140°C to generate the isocyanate.
  • Compound 54 is treated with a Grignard reagent to give the corresponding alcohol and as previously described, converted to compound 57.
  • Compound 55 is treated with NH 3 /Ph 3 P/DEAD (or treated with CBr 4 /Ph 3 P and the bromide converted to the amine 63 with ammonia).
  • Treatment with phosgene followed by sulfonamide yields 64, treatment of which with a base and an alkyl or benzylic halide gives compounds 65.
  • Aldehyde 10 is treated with a silylated source of hydroxyl or thiol at 80-130 °C, and the silyl group removed by fluoride treatment.
  • Compound 66 is then treated with an aryl or heteroaryl methylene bromide with a base such as a tertiary amine in CHC1 3 or benzene to yield aldehyde 67.
  • Emmons-Horner (or Wittig reaction) with LDA results in compound 68 via Method A.
  • a suitably substituted bromo toluene 24 is converted to the anion in an etheral solvent at low temperature and trapped with an aldehyde of an aryl or heteroaryl.
  • the resulting alcohol is oxidized with Mn0 2 , Jones' reagent, PDC, PCC or any other oxidant.
  • Benzylic bromination followed by oxidation with N-methyl morpholine N-oxide yields a ketoaldehyde.
  • Emmons-Horner and Method A gives the cinnamic sulfonamides 72.
  • Biological activity and thus utility for the compounds of formula I as modulators of prostaglandin mediated diseases can be demonstrated in accordance with the following assayswhich demonstrate prostanoid antagonist or agonist activity in vitro and in vivo and their selectivity.
  • the prostaglandin receptors investigated were DP, EP EP 2 , EP 3 , EP 4 , FP, IP and TP.
  • HEK 293(ebna) cell line Prostanoid receptor cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells.
  • HEK 293(ebna) cells expressing the individual cDNAs were grown under selection and individual colonies were isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.
  • HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays.
  • Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the appropriate radioligand.
  • the reaction is initiated by addition of membrane protein.
  • Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations.
  • Non-specific binding is determined in the presence of 1 ⁇ M of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand affinity.
  • Incubations contain 100 ⁇ M RO-20174 (phosphodiesterase type rV inhibitor, available from Biomol) and, in the case of the EP 3 inhibition assay only, 15 ⁇ M forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP levels are then measured.
  • For calcium mobilization assays cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations.
  • second messenger responses are expressed as a function of ligand concentration and both EC 50 values and the maximum response as compared to a prostanoid standard are calculated.
  • the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both K B and slope values are calculated.
  • Female Lewis rats (body weight -146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group.
  • Six groups of 10 rats each were injected into a hind paw with 0.5 mg of Mycobacterium butyricum in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant.
  • Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection.
  • the rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant.
  • radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26.
  • test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days.
  • the compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.
  • the ethyl ester can be prepared as well in the same way or from the 2-methyl benzaldehyde ( 5.00 g; 41.6 mmol) and triethyl phosphonoacetate (9.9 mL; 50.0 mmol) in 150 mL ot toluene at 0 C C, to which was added portionwise NaH (63.0 mmol). After 2 h of stirring the mixture was quenched with NH 4 OAc (25%) and extracted with EtOAc. The solvent was removed to give 7.1 g of the ethyl cinnamate. Step 2: Ethyl (E)-3-.2-(bromomethyl)phenyl1-2-propenoate
  • Step 3 Ethyl (E)-3-(2-.4-(methylthio)benzvHphenyl.-2-propenoate
  • Step 5 N-((E)-3-f2-.4-(methylthio)benzyllphenyl ⁇ -2-propenoyl)-2- thiophenesulfonamide (17)
  • 2-Thiophenesulfonamide was prepared from the corresponding sulfonyl chloride with 2.2 equivalent of NH 4 OH in THF at 0 °C. The solution was brought to r.t. and left 2 h. It was then quenched with NaHC0 3 and extracted with EtOAc. The organic phase was dried over Na 2 SO 4 and the solvent removed. The crude product was crystallized in toluene/EtOAc.
  • Step 2 (E)-3-.2-.(3-methyl-lH-l-indolyl)methyl1phenyl ⁇ -2-propenoic acid
  • Step 3 N2-((E)-3-f2-r ( 3-methyl-lH-l-indolyl)methvnphenyll-2-propenoyl)- 2-thiophenesulfonamide (3)
  • the coupling reaction of the previous acid (196 mg; 0.67 mmol) was done according to step 5 of example 1 to yield 134 mg of the title compound.
  • step 2 The benzyl bromide (500 mg) of example 1, step 2 was treated with 2-naphthylboronic acid according to the same procedure previously described to yield 360 mg of the title compound.
  • Step 1 Ethyl (E)-3-r2-(3.4-dichlorobenzyl)phenyl1-2-propenoate
  • the benzyl bromide (500 mg) of example 1 was treated with 3,4-dichlorobenzeneboronic acid according to the same procedure described in step 3 of example 1 to yield 410 mg of the title compound.
  • Step 3 N- ⁇ (E)-3-.2-(3.4-dichlorobenzyl)phenvn-2-propenoyl.-2- thiophenesulfonamide (8)
  • the coupling reaction of the previous acid (170 mg; 0.55 mmol) was done according to step 5 of example 1 to yield 110 mg of the title compound.
  • the acid was converted to the sodium salt with 1 equivalent of NaOH.
  • Step 1 Ethyl (E)-3- ⁇ 2-.naphthyloxy)methyriphenyl.-2-propenoate
  • Step 2 (E)-3-.2-.naphthyloxy)methyl1phenyl ⁇ -2-propenoic acid
  • Step 3 N-((E)-3-!2-.(2-naphthyloxy)methyllDhenyl)-2-propenoyl)-2- thiophenesulfonamide (20)
  • Step 3 Ethyl (E)-3-.2-(2-naphthylsulfinyl)phenyll-2-propenoate
  • the previous ester (3.00 g; 8.97 mmol) in 45 mL of dichloromethane was treated with 1.1 equivalent of mCPBA at 0 °C for 1 h.
  • the mixture was quenched with sodium thiosulf ⁇ te and extracted with EtOAc.
  • the organic phase was dry over Na 2 S0 4 and the crude purified by silica gel chromatography (30% EtOAc in hexane) to yield 2.35 g of the title compound.
  • Step 5 2-!(E)-3-r2-(2-naphthylsulfinyl)phenyl1-2-propenoyl.-2- thiophenesulfonamide (21)
  • the sodium salt was prepared with IN NaOH. Elemental analysis calcd. for C 23 H 16 NNa0 4 S 3 .l/2H 2 0: C, 55.36; H,3.40; N, 2.81; S,
  • Step 1 Ethyl ( E ) -3-.2- ( 2-naphthyloxy)phenyll-2-propenoate
  • Step 2 Ethyl (E)-3-r2-(2-naphthyloxy)phenyll-2-propenoate
  • the previous aldehyde (2.00 g; 8.0 mmol) was converted to the title compound according to step 1 of example 1 to yield 2.52 g .
  • Step 4 N-.(E)-3-.2-(2-naphthyloxy)phenyl.-2-propenoyl)-2- thiophenesulfonamide (28)
  • Step 1 [2-(2-naphthylthio)phenynmethanol To 2-(2-naphthylthio) benzaldehyde (7.24 g; 27.4 mmol from
  • Example 6 step 1) in 70 mL of methanol and 30 mL of THF at 0 °C was added NaBH 4 (54.8 mml) portionwise. After lh at 0 °C, the solution was brought to r.t. and quenched with water. After dilution with EtOAc, the solution was washed with water and brine. The organic phase was dry over Na 2 S0 4 , filtered and the crude purified by silica gel chromatography to yield 6.71 g of the title compound.
  • NaBH 4 54.8 mml
  • Step 2 .2-(2-Naphthylsulfonyl)phenyll methanol
  • step 2 To the alcohol of step 2 (250 mg; 0.84 mmol) in ether at 0 °C was added the previous isocyanate (2 equivalent) and let stirred lh at 0 °C. The solution was quenched with water and extracted with EtOAc. The organic phase dry over Na 2 S0 4 , filtered and the crude purified by silica gel chromatography (5% CH 3 OH in CH 2 C1 2 ) to yield 300 mg of the title compound.
  • Step 1 Ethyl 2-f2-(2-naphthylmethyl)phenyll-l-cyclopropanecarboxylate
  • the ethyl ester (300 mg; 0.95 mmol) of step 1 in example 3 and Pd(OAc) 2 (10 mg) were treated with diazomethane at 0° C for lh.
  • Step 2 2-.2-(2-naphthylmethyl)phenyl.-l-cyclopropanecarboxylic acid
  • the previous ester 300 mg; 0.91 mmol
  • Step 3 N-((2-.2-(2-naphthylmethyl)phenyllcyclopropyl.carbonyl-2- thiophenesulfonamide (45)
  • Step 6 N-((E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoyl)- 5-bromo-2-methoxybenzenesulfonamide (46)
  • step 5 To the acid from step 5 (190 mg, 0.482 mmol) in CH 2 C1 2 was added DMF (10 ⁇ L) and oxalyl chloride (60 ⁇ L) at 0°C and the mixture was warmed to r.t. for an hour and concentrated to dryness. The resulting acid chloride was redissolved in CH 2 C1 2 :THF 1:1 (10 mL) and 5- bromo-2-methoxybenzenesulfonamide (154 mg, 1.2 equiv., from step 6) and Et 3 N (135 ⁇ L, 2 equiv.) were added at 0°C. The mixture was then warmed to r.t.
  • Step 1 N- ( (E)-3-f 2-naphthylmethyl)phenyl )1 -2-propenoyl ⁇ -5-bromo-2- methoxy-l-benzenesulfonamide (301)
  • the carboxylic acid (400 mg; 1.22 mmol) of example 3 step 2 was coupled with 5-bromo-2-methoxy-l-benzenesulfonyl chloride according to the procedure of step 5 in example 1 to yield 284 mg of the title compound.
  • Step 3 Ethyl (E)-3-[2-(bromomethyl)-5-chlorophenyll-2-propenoate
  • the previous ester (16.66 g; 74.1 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 9.0 g of the title compound.
  • Step 5 (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyll-2-propenoic acid
  • the hydrolysis of the previous ester (1.14 g) was done according to Step 4 of example 1 to yield 0.99 g of the title compound.
  • Step 6 N-f(E)-3-l5-chloro-2-(2-naphthylmethyl)phenvn-2-propenoyl ⁇ -2- thiophenesulfonamide (303)
  • Step 1 Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate To 2-bromo-4-chloro toluene (20.0g; 97.3 mmol) in 300 mL of THF at -78 oC was added n-BuLi 2.5 M (40.8 mL) dropwise. After 20 min. 1-formylpi ⁇ eridine (11.4 mL; 103.0 mmol) in 10 mL of THF was added dropwise. After 30 min the reaction mixture was brought to 0°C and quenched with HCl (10%) and diluted with EtOAc.
  • this procedure can be done in one reaction vessel.
  • the flask is brought to rt and the phosphonoacetate in THF is added.
  • Step 2 Ethyl(E)-3-.2-(bromomethyl)-5-chlorophenyll-2-propenoate The bromination was done according to step 2 of example 1 to provide the title compound in 45% yield.
  • Step 4 Ethyl (E)-3- ⁇ 4-chloro-2-[(6fluoro-2-naphthyl)methyllphenyl)-2- propenoate
  • Step 5 (E)-3- ⁇ 4-Chloro-2- (6-fluoro-2-naphthyl)methyllphenyll-2- propenoic acid, sodium salt
  • the title compound was prepared from 2-(4- fluorophenyl)acetyl chloride according to step 3 of example 13.
  • Step 2 Ethyl (E ) -3- ( 5-chloro-2-.(6-chloro-2-naphthyl)methyl1phenyl)-2- propenoate
  • Step 3 ( E ) -3- ( 5-Chloro-2-r ( 6-chloro-2-naphthyl)methyllphenyl ⁇ -2- propenoic acid, sodium salt
  • Step 1 5-Bromo -N-((E)-3-f5-chloro-2-_(6-chloro-2- naphthyl)methyl1phenyl ⁇ -2-propenoyl)-2-methoxybenzenesulfonamide
  • the coupling reaction of the acid of Example 15 Step 3 (500 mg; 1.4 mmol) was done according to step 5 of example 1 with 5-bromo- 2-methoxybenzesulfonamide to yield 662 mg (74%) of the title compound.
  • the sodium salt was prepared with IN NaOH.
  • Step 2 Ethyl (E)-3-(5-chloro-2-..6-difluoromethoxy)-2- naphthyl.methyl ⁇ phenyl)-2-propenoate
  • the corresponding boronic acid of the previous halide was coupled according to step 3 of example 1 of the title compound in 57% yield.
  • Step 3 (E)-3-(5-Chloro-2-( [6-difluoromethoxy)-2-naphthyllmethyl)phenyl)- 2-propenoic acid, sodium salt
  • Step 1 5-Bromo -N-.(E)-3-(5-chloro-2-U6-difluoromethoxy)-2- naphthyllmethyl)phenyl)-2-propenoyll-2-methoxybenzennesulfonamide
  • Step 1 Ethyl (E)-3-.2-(3.4-dichlorobenzyl)-5-chlorophenyl)-2-propenoate
  • the benzyl bromide of step 2 of example 13 was treated with
  • Step 2 (E)-3-r2-(3.4-Dichlorobenzyl)-5-chlorophenyl)-2-propenoic acid. sodium salt
  • Step 1 5-Bromo-N- ⁇ (E)-3-r5-chloro-2-)3.4-dichlorobenzyl)phenyll-2- propenoyll-2-methoxybenzenesulfonamide
  • Step 1 Ethyl (E)-3-f4-chloro-2-.(2-naphthylmethyl)phenyll-2-propenoate 2-Bromo-5-chloro toluene (20.0 g) was converted to the corresponding aldehyde and then to the cinnamate according to step 1 of example 13. This cinnamate was converted to the benzylic bromide according to step 2 of example 1 and coupled via a Suzuki coupling reaction according to step 3 of example 1 with naphthalene boronic acid to yield the title compound.
  • Step 2 (E)-3-.4-Chloro-2-[(2-naphthylmethyl)phenyl ⁇ -2-propenoic acid (530)
  • Step 3 5-Bromo-N-f .
  • the coupling reaction of the acid of Step 2 (0.296 g; 0.89 mmol) was done according to step 5 of example 1 with 5-bromo-2- methoxybenzesulfonamide to yield 213 mg (42%) of the title compound.
  • the sodium salt was prepared with IN NaOH.
  • Step 1 (2-Bromo-4-methoxyphenyl)(2-naphthyl)methanone AICI3 (17.48 g; 131.1 mmol) was added portionwise to a mixture of 3-bromocresol (16.04 g; 87.4 mmol) and 2-naphthoyl chloride (25.00 g; 131.1 mmol) in 50 mL of CHC13 gave 14.0 g (47%) of the title compound.
  • the naphthalene of Step 2 was converted to the corresponding aldehyde according to the step 1 of example 13 in 98% yield. This aldehyde was then converted to the cinnamate according to step 1 of example 13 in 90% yield.
  • Step 4 ( E ) -3-.5-Methoxy-2- ( 2-naphthmethyl)phenyl.-2-propenoic acid
  • the hydrolysis of the ester of Step 3 (2.83 g; 8.2 mmol) was done according to step 4 of example 1 to yield 2.16 g (83%) of the title compound.
  • the sodium salt was prepared with IN NaOH.
  • Step 1 5-Bromo-2-methoxy-N-!(E)-3-r5-methoxy-2-(2- naphthylmethyl)phenyll-2-propenoyl ⁇ benzenesulfonamide
  • Step 1 Ethyl(E)-3-r5-chloro-2-(4-chlorobenzyl)phenvn-2-propenoate
  • the benzyl bromide of step 2 of example 13 was coupled in a
  • Step 4 (E)-3- ⁇ 2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl ⁇ -2- propenoic acid (493)
  • Step 5 (E)-3- ⁇ 2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl ⁇ -N- ⁇ ( 5-bromo-2-methoxyphenyl)sulfonyll-2-propenamide
  • step 2 The ester (901 mg, 3.14 mmol) of example 13, step 2 was coupled with benzo[b]thiophene-2-boronic acid (from Lancaster).
  • Step 3 (E)-3-[2-(Benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-N-[(5- bromo-2-methoxyphenyl)sulfonyl1-2-propenamide
  • the previous acid 264 mg; 0.85 mmol
  • 5- bromo-2-methoxybenzenesulfonamide of example 10 was coupled with 5- bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 287 mg of the title compound.
  • Step 1 Ethyl (E)-3-[5-fluoro-2-(indol-5-ylmethyl)phenyll-2-propenoate
  • step 2 was coupled with 5-indolyl boronic acid and NaHC0 3 in DME according to the procedure described in step 3 of example 10 to yield 1.08 g of the title compound.
  • ⁇ NMR (acetone-d 6 ) ⁇ 1.26 (3H, t), 4.17 (2H, q), 4.21 (2H, s),
  • Step 2 Ethyl (E)-3-(5-fluoro-2-( ⁇ l-benzylindol-5-yl1methyl ⁇ phenyl)-2- propenoate
  • Step 1 The indole of Step 1 (621 mg; 1.92 mmol) was coupled with benzyl bromide according to the procedure described in step 1 of example 2 to yield 678 mg of the title compound.
  • Step 3 (E)-3-(5-Fluoro-2-( [l-benzylindol-5-ynmethyllphenyl)-2-propenoic acid) (540)
  • the hydrolysis of the ester of Step 2 (678 mg) was done according to step 4 of example 1 to yield 276 mg of the title compound.
  • Step 4 N-(E)-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-(5-fluoro-2- ⁇ [l- benzylindol-5-yllmethyl ⁇ phenyl)-2-propenamide
  • the acid of Step 3 (219 mg; 0.57 mmol) was coupled with 5- bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 149 mg of the title compound.
  • Step 1 Ethyl (E)-3-(3-methyl-2-pyridyl)-2-propenoate To a solution of 2-bromo-3-methylpyridine (10.36 g; 60.2 mmol) in 120 mL of THF at -100 °C was added dropwise a 1.6 M solution of n-BuLi (65.6 mmol). After 20 min of stirring at that temperature, 1- formylpiperidine (7.65 g) in 10 mL of THF was added and the solution was warmed to r.t.. After 30 min of stirring at r.t., triethyl phosphonoacetate (13.7 mL; 69.1 mmol) was added dropwise below 30 °C .
  • Step 3 Ethyl ( E ) -3-.3-. ( 5-chloroindolyl ) methyl1-2-pyridyll-2-propenoate
  • the benzylic bromide of Step 2 (1.33 g; 4.91 mmol) was coupled with 5-chloroindole according to the procedure described in step 1 of example 2 to yield 1.22 g of the title compound.
  • Step 4 ( E ) -3-.3-. ( 5-Chloroindolyl)methyll-2-pyridyl ⁇ -2-propenoic acid
  • Step 5 N-(E)-r(2.4-Dimethyl(1.3-thiazol-5-yl))sulfonyl.-3-f3-.(5- chloroindolyl)methyll(2-pyridyl))-2-propenamide
  • the acid of Step 4 (283 mg; 0.90 mmol) was coupled with 2,4- dimethyl-l,3-thiazole-5-sulfonamide (from Maybridge Chemical) according to step 5 of example 1 to yield 315 mg of the title compound.

Abstract

Compounds of formula (I), as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.

Description

CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
BACKGROUND OF THE INVENTION The present invention relates to compounds which are useful for treating or preventing prostaglandin mediated diseases, methods of treatment and pharmaceutical compositions containing such compounds. The compounds are structurally different from conventional NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.
Two review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: Eicosanoids: From Biotechnology to Therapeutic Applications, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and
Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87. An article from The British Journal of Pharmacology (1994, 112, 735-740) suggests that Prostaglandin E2 (PGE2) exerts allodynia through the EPi receptor subtype and hyperalgesia through EP2 and EP3 receptors in the mouse spinal cord.
Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties, and in addition inhibit hormone-induced uterine contractions. Moreover, the compounds have anti-cancer effects.
The compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects. SUMMARY OF THE INVENTION
The present invention relates to compounds represented by formula I:
Figure imgf000004_0001
I as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein:
HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(0)n and N(0)m wherein m is 0 or 1 and n is 0, 1 or 2; A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)- , -C(R7)2-W- , -W-C(R7)2 - , -CR7(OR20)- , -C(R7)2 - , -C(R7)2-C(OR20)R7 - , -C(R7)2- C(R7)2- or -CR7=CR7- , wherein W represents O, S(0)n or NR17, with n as previously defined and Rl7 as defined below; X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0)m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other; Y represents O, S(O)n , NR17, a bond or -CR18 = CR18- ; B represents - (C(Rl8)2)p-Y- (C(Rl8)2)q - wherein p and q are independently 0-3, such that when Y represents O, S(0)n , NR17 or -CR18 = CR18- , p + q = 0-6, and when Y represents a bond, p + q is 1-6;
Z is OH or NHSO2R19 ; R1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(Ra)4_9 , -
(C(R4)2)pSR5, -(C(R4)2)pOR8, -(C(R4)2)pN(R6)2, CN, N02, -(C(R4)2)pC(R7)3, - C02R9, -CON(R6)2 or -(C(R )2)pS(0)nR10, wherein n and p are as previously defined; each R4 is independently H, F, CF3 or lower alkyl, or two R4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0)m; each R5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET, lower alkenyl-HET or -(C(R18)2 )pPh(Rn)θ- 2; each R6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn and when two R6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0)n or N(0)m; each R7 is independently H, F, CF3 or lower alkyl, and when two R7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(O)n and N(O) ; each R$ represents H or R5; each R9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn; each R10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(Rn)θ-3, CH2Ph(R11)0-3 or N(R6)2 ; each R11 is independently lower alkyl, SR20, OR20, N(R6)2,
-C02R12, -CON(R -C(0)R12, CN, CF3, N02 or halogen; each R12 is independently H, lower alkyl or benzyl; each R13 is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(Rb)2, C02R12, CN, CF3 or NO 2 > R14 and Rl5 are independently lower alkyl, halogen, CF3,
OR16, S(0)nR16 or C(R16)2OR17 ; each R16 is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF3. each R17 is independently H, lower alkyl or Bn; each R18 is independently H, F or lower alkyl, and when two
R18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0)n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF 3 '
HET(Ra)4_g, lower alkyl-HET(Ra)4_9 or lower alkenyl-HET(Ra)4_9; each R20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3 or Ph(R13)2 and each Ra is independently selected from the group consisting of:
H, OH, halo, CN, NC>2. amino, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, Ci_6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkylamino, di-Ci-βalkylamino, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(O) C2- βalkynyl, CO2H, Cθ2Ci-6alkyl, Cθ2C2-6alkenyl, and CCtøCtø-βalkynyl, said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(0)C2-6alkynyl, CO2H, Cθ2Cι_6alkyl, Cθ2C2-6alkenyl, Cθ2C2-6alkynyl, NH2, NHCi-βalkyl and N(Ci-6alkyl)2. Pharmaceutical compositions are also included which are comprised of a compound of formula I in combination with a pharmaceutically acceptable carrier.
A method of treating or preventing a prostaglandin mediated disease is also included which is comprised of administering to a mammalian patient in need thereof, a compound of formula I in an amount which is effective for treating or preventing a prostaglandin mediated disease.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to carboxylic acids and acylsulfonamides, which are ligands at prostaglandin receptors, as well as a method for treating or preventing a prostaglandin mediated disease comprising administering to a patient in need of such a treatment of an amount of compound of Formula I which is effective for treating or preventing a prostaglandin mediated disease.
The invention described in this patent application is described using the following definitions unless otherwise indicated. HET represents a 5-12 membered aromatic ring system containing 0-3 heteroatoms selected from O, S(O)n and N wherein n is 0,
1 or 2. HET may be substituted with up to three substituents on the aromatic ring system, Rl, R2 and R3. "Aromatic ring systems" as used herein includes aryl and heteroaryl groups such as benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole. HET2 is a subset of HET and represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.
Aryl refers to aromatic 6-10 membered groups having 1-2 rings and alternating (resonating) double bonds. Examples include phenyl, biphenyl and naphthyl.
Heteroaryl refers to aromatic 5-12 membered groups having alternating (resonating) double bonds and containing from 1-4 heteroatoms selected from O, S(0)n and N. Examples include the following: : quinoline, furan, benzofuran, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, oxazole, indole, isoindole, pyridine, isoquinoline, imidazole, thiazole, triazole, 1,3- methylene dioxobenzene, pyrrole and naphthyridine,
Heterocyclyl refers to non- aromatic 5-12 membered cyclic groups having 1-4 heteroatoms selected from O, S(0)n and N. Examples of heterocyclic groups are piperidine, piperazine, pyrrolidine, tetrahydrofuran, tetrahydropyran and morpholine.
X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0)m, and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group X in positions which are ortho relative to each other. Examples are selected from the group consisting of: phenyl, naphthyl, biphenyl, quinoline, furan, benzofuran, pyridyl, pyrrole, thiophene, benzothiophene, thiazole, benzothiazole, 1,2,5- thiadiazole, triazole, 1,2-methylenedioxybenzene, thienopyridine, oxazole and indole.
The terms alkyl, alkenyl, and alkynyl mean linear, branched, and cyclic structures and combinations thereof.
"Lower alkyl" means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, s- and t-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, and the like. When propyl and butyl are recited without the isomeric form being specified, these include all isomers thereof. "Lower alkenyl" means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2- methyl-2-butenyl, cyclopropen-1-yl, cyclohexen-3-yl and the like. When cis or trans is not specified, both are intended in pure form as well as in the form of a mixture of isomers.
"Lower alkynyl" means alkynyl groups of 2 to 7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3- methyl-1-pentynyl, 2-heptynyl, 2-(cyclopropyl)ethenyl, 3-(cyclobutyl)-l- propynyl and the like. Halogen (halo) includes F, Cl, Br and I.
The following abbreviations have the indicated meanings:
AIBN = 2.2'-azobisisobutyronitrile
B.P. = benzoyl peroxide
Bn = benzyl
CC14 = carbon tetrachloride
D -0(CH2)3θ-
DAST = diethylamine sulfur trifluoride
DCC = dicyclohexyl carbodiimide
DCI = l-(3-dimethylaminopropyl)-3-ethyl carbodiimide
DEAD = diethyl azodicarboxylate
DIBAL = diisobutyl aluminum hydride
DME = ethylene glycol dimethylether
DMAP = 4-(dimethylamino)pyridine
DMF = N,N-dimethylformamide
DMSO = dimethyl sulfoxide
Et3N = triethylamine
LDA = lithium diisopropylamide m-CPBA metachloroperbenzoic acid
NBS = N-bromosuccinimide
NSAID = non-steroidal anti-inflammatory drug
PCC = pyridinium chlorochromate
PDC = pyridinium dichromate
Ph = phenyl
1,2-Ph = 1,2-benzenediyl
Pyr = pyridinediyl
Qn = 7-chloroquinolin-2-yl
Rs = -CH2SCH2CH2Ph r.t. = room temperature rac. = racemic
THF = tetrahydrofuran
THP _z tetrahydropyran-2-yl
1 Alkvl group abbreviations
Me = methyl
Et = ethyl n-Pr = normal propyl i-Pr = isopropyl i n-Bu = normal butyl i-Bu = isobutyl s-Bu = secondary butyl t-Bu = tertiary butyl c-Pr = cyclopropyl
) c-Bu = cyclobutyl c-Pen = cyclopentyl c-Hex = cyclohexyl
It is intended that the definition of any substituent (e.g., R R , etc.) in a particular molecule be independent of its definition elsewhere in the molecule. Thus, -N(R )2 represents -NHH, -NHCH , -
NHC 6 H 5 , and the like.
In one aspect of the invention, the invention relates to a compound represented by formula I:
R1R2R3— HET O \
X — B
I as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein: HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)n and N(0)m wherein m is 0 or 1 and n is 0, 1 or 2;
A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)- , -C(R7)2-W- , -W-C(R7)2 - , -CR7(OR20)- , -C(R7)2 - , -C(R7)2-C(OR20)R7 - , -C(R7)2- C(R7)2 or CR7=CR7, wherein W represents O, S(0)n or NR17, with n as previously defined and Rl7 as defined below;
X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0)m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other; Y represents O, S(O)n , NR17, a bond or -CR18 = CR18- ; B represents - (C(Rl8)2)p-Y- (C(Rl8)2)q - wherein p and q are independently 0-3, such that when Y represents O, S(0)n , NR17 or -CR18 = CR18- , p + q = 0-6, and when Y represents a bond, p + q is 1-6;
Z is OH or NHS02R19 ;
R1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(Ra)4_9 , - (C(R4)2)pSR5, -(C(R4)2)pOR8, -(C(R4)2)pN(R6)2, CN, N02, -(C(R4)2)pC(R7)3, -
CO2R9, -CON(R6)2 or
-(C(R4)2)pS(0)nR10, wherein n and p are as previously defined; each R4 is independently H, F, CF3 or lower alkyl, or two R4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0)m; each R5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET, lower alkenyl-HET or -(C(R18)2 )pPh(Rπ)θ-
2; each R6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn and when two R6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0)n or N(O)m; each R7 is independently H, F, CF3 or lower alkyl, and when two R7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(0)n and N(O)m; each R represents H or R5; each R9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn; each R10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(Rn)θ-3, CH2Ph(Ru)θ-3 or N(R6)2 ; each R11 is independently lower alkyl, SR20, OR20, N(R6)2, -C02R12, -CON(R6)2, -C(O)R12, CN, CF3, N02 or halogen; each R12 is independently H, lower alkyl or benzyl; each R13 is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R6)2, C02R12, CN, CF3 or N02 ;
R14 and Rl5 are independently lower alkyl, halogen, CF3, OR16, S(0)nR16 or C(R16)2OR17 ; each R16 is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF3. each R17 is independently H, lower alkyl or Bn; each R18 is independently H, F or lower alkyl, and when two R18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0)n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF 3 >
HET(Ra)4_9, lower alkyl-HET(Ra)4_9 or lower alkenyl-HET(Ra)4_9; each R20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3 or Ph(R13)2 and each Ra is independently selected from the group consisting of: H, OH, halo, CN, NO2, amino, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkylamino, di-Ci- 6alkylamino, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(O) Ctø-βalkynyl, CO2H, Cθ2Ci-6alkyl, Cθ2C2-6alkenyl, and Cθ2C2-6alkynyl, said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialk lamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF3, C(O)Ci-6alkyl, C(0)C2-6alkenyl, C(0)C2-6alkynyl, CO2H, Cθ2Ci-6alkyl, CO2C2-6alkenyl, Cθ2C2-6alkynyl, NH2, NHCi-βalkyl and N(Ci-6alkyl)2.
In another embodiment of the invention, the invention relates to compounds represented by formula I:
Figure imgf000012_0001
I as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein: HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(O)n and N(0) wherein m is 0 or 1 and n is 0, 1 or 2;
A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)- , -C(R7)2-W- , -W-C(R7)2 - , -CR7(OR20)- , - C(R7)2 - , -C(R7)2-C(OR20)R7 - , -C(R7)2- C(R7)2 or CR7=CR7, wherein W represents O, S(0)n or NR17, with n as previously defined and Rl7 as defined below;
X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0)m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other; Y represents O, S(O)n ; NR17, a bond or -CR18 = CR18- ; B represents - (C(Rl8)2)p-Y- (C(Rl8)2)q - wherein p and q are independently 0-3, such that when Y represents O, S(O)n , NR17 or -CR18 = CR18- , p + q = 0-6, and when Y represents a bond, p + q is 1-6;
Z is OH or NHSO2R19 ;
R1 R and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(Ra)4_9 .
-(C(R4)2)pSR5, -(C(R4)2)pOR8, -(C(R4)2)pN(R6)2, CN, N02, -(C(R4)2)pC(R7)3, -C02R9, -CON(R6)2 or -(C(R4)2)pS(0)nR10, wherein n and p are as previously defined; each R4 is independently H, F, CF3 or lower alkyl, or two R4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0)m; each R5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET, lower alkenyl-HET or -(C(R18)2 )pPh(Rn)θ- 2; each R6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn and when two R6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0)n or N(0)m; each R7 is independently H, F, CF3 or lower alkyl, and when two R7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(0)n and N(0)m; each R represents H or R5; each R9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn; each R10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(Ru)θ-3, CH2Ph(Rn)0-3 or N(R6)2 ; each R11 is independently lower alkyl, SR20, OR20, N(R6)2,
-C02R12, -CON(R6)2, -C(0)R12, CN, CF3, N02 or halogen; each R12 is independently H, lower alkyl or benzyl; each R is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R6)2, CO2R12, CN, CF3 or NO 2 >
R14 and Rl5 are independently lower alkyl, halogen, CF3, OR16, S(0)nR16 or C(R16)2OR17 ; each R16 is independently H, lower alkyl, lower alkenyl, Ph, Bn, CHF2 or CF3. each R17 is independently H, lower alkyl or Bn; each R18 is independently H, F or lower alkyl, and when two R18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(O)n or N; each R19 is lower alkyl, lower alkenyl, lower alkynyl, CF3 , HET2(Ra)4_9, lower alkyl-HET2(Ra)4_9 0r lower alkenyl-HET2(Ra)4_9, wherein HET2 represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl; each R20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF2 , CF3 or Ph(R13)2 and each Ra is independently selected from the group consisting of: H, OH, halo, CN, N02, amino, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-6alkylamino, di-Cl- βalkylamino, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(O) C2-6alkynyl, C02H, Cθ2Ci-6alkyl, Cθ2C2-6alkenyl, and Cθ2C2-6alkynyl, said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF3, C(0)Cl-6alkyl, C(0)C2-6alkenyl, C(0)C2-6alkynyl, CO2H, CCtøCi-βalkyl, Cθ2C2-6alkenyl, Cθ2C2-6alkynyl, NH2, HCi-βalkyl and N(Ci-6alkyl)2.
An embodiment of the present invention which is of particular interest is represented by formula I wherein HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,2-methylenedioxybenzene and pyrrole.
More particularly, an embodiment of the present invention is represented by formula I wherein HET is selected from the group consisting of: benzene, biphenyl, naphthylene, indole, thiophene, benzofuran and quinoline. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.
Another embodiment of the present invention that is of particular interest is represented by formula I wherein A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO2, CH2, -C(O)- , -OCH2-, -CHOH- , -C(OH)(CH3)- and -CH2-0- .
More particularly, A is selected from the group consisting of: : S, S(O), SO2, CH2, -C(O)-. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I. Another embodiment of the present invention that is of particular interest is represented by formula I wherein X represents phenyl optionally substituted with R14 and R15. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I. More particularly, X represents phenyl and R14 and R15 are absent or represent halo. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.
Another embodiment of the present invention that is of particular interest is represented by formula I wherein B is CH=CH or 1,2-cyclopropyl, and in particular, where B is CH=CH in the E-isomeric form. Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I.
Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is NHS02R19 . Within this subset of compounds of the invention, all other variables are as originally described with respect to formula I. Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is NHS02R19 and R19 represents a member selected from the group consisting of: lower alkyl and HET(Ra)3. Within this aspect of the invention, HET is selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.
Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z is NHSO2R19 and R19 represents benzene or thiophene, substituted with R R2R3. Another embodiment of the present invention that is of particular interest is represented by formula I wherein Z represents OH. Within this subset, all other variables are as originally defined.
A subset of compounds that is of particular interest is defined with respect to formula I wherein: HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole; A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO2, CH2, -C(O)- , -OCH2- , -CHOH- , - C(OH)(CH3 )- and -CH2-O-;
X represents phenyl optionally substituted with R14 and R15 ; B is CH=CH; Z is NHS02R19 and
R19 represents a member selected from the group consisting of: lower alkyl and HET(Ra)3.
Examples of compounds of the present invention are shown in Tables I and II below.
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000036_0002
Figure imgf000036_0003
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers. The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of Formula I and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably
0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain from about 0.5 mg to about 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
For the treatment of any of the prostanoid mediated diseases compound I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, solutions, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally- occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compound I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient. The ability of the compounds of Formula I to interact with prostaglandin receptors makes them useful for treating, preventing or reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject. This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent or ameliorate prostaglandin mediated diseases and conditions in mammals and especially in humans: Pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as immune and autoimmune diseases. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. Compound I may also be of use in the treatment and/or prevention prostaglandin-mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis. Compound I will also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, the treatment of glaucoma, for the prevention of bone loss (treatment of osteoporosis) and for the promotion of bone formation (treatment of fractures) and other bone diseases such as Paget's disease. By virtue of its prostanoid or prostanoid antagonist activity, compound I will prove useful as an alternative to NSAID'S particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; thrombosis, occlusive vascular diseases; those prior to surgery or taking anti-coagulants. Compound I will also be useful as a cytoprotective agent for patients under chemotherapy.
Compound of Formula I, will be useful as a partial or complete substitute for conventional antiinflammatory or analgesic compounds in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin E2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a COX-2 selective NSAID; a conventional NSAID; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; another prostaglandin ligand including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition, the invention encompasses a method of treating prostaglandin E2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above. Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius.
Boronic acids and esters can be prepared from the corresponding halide according to literature procedure and reference cited therein (Charette, A.B.; Giroux, A. J. Org. Chem. 1996, 61, 8718; Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 1995, 60, 7508; Miyaura, N.; Suzuki, A. Chem. Rev, 1995, 95, 2457; Murata, M.; Watanabe, S.; Masuda, Y. J. Org. Chem. 1997, 62, 6458; Watanabe, T. Miyaura, N.; Suzuki, A. Synlett, 1992, 207; Maddaford, S.; Keay, B.A. J. Org. Chem. 1994, 59, 6501; Cristofoli, W.A.; Keay, B.A. Tetrahedron Lett. 1991, 32, 5881; Passafaro, M.S.; Keay, BA. . Tetrahedron Lett. 1996, 37, 429; Serafin, B.; Makosza, M. Tetrahedron, 1963, 19, 821). In some cases, the triflate, the tin or the zinc derivatives may be used instead of the boronic acid.
Method A
Cinnamic ester 1 is treated with a brominating agent such as NBS in a refluxing inert solvent such as CC14, with the use of an initiator like benzoyl peroxide or light. The resulting benzylic bromide is reacted in a Suzuki coupling reaction with the appropriate boronic acid or ester, a catalyst such as tetrakis(triphenylphosphine) palladium and cesium fluoride or Na2C03 or a base in an inert refluxing solvent such as DME at 80-90° C. The new cinnamic ester 3 is hydrolyzed with aqueous sodium hydroxide to afford the acid 4 that is converted to the cinnamic sulfonamide 5 with a coupling reagent such as DCC or DCI in CH2C12 at r.t.
Method B
Cinnamic ester 2 is treated with an aryl or heteroaryl mercaptan, alcohol or amine, and with a base such as a hydride or an amine in benzene or THF at 0-23° C. The resulting cinnamic ester 6 is converted to 7 according to Method A. If W= sulfur, it is oxidized to the sulfoxide or sulfone 8 with hydrogen peroxide, m-CPBA or other peracetic acid. The cinnamic ester 8 is converted to 9 according to Method A.
Method C The aldehyde 11 is prepared by an addition-elimination of a mercapto, hydroxy or amino aryl or heteroaryl with a base such as I^COg in refluxing CHC13. If needed a higher boiling point solvent can be used. This type of rection can also be performed with CuO in DMF. An Emmons-Horner type reaction (or Wittig) in toluene at r.t. followed by Method A (or oxidation as described in Method B) results in the cinnamic sulfonamide 13.
Method D
Acetal 14 that came from an acetalization from a suitably substituted bromo benzaldehyde is converted to the Grignard reagent with magnesium in an etheral solvent at reflux and quenched with an aryl or heteroaryl ketone. The alcohol 16 is reacted with an halide and a base (or protected as the o-nitrobenzyl, and removed at the end of the sequence) to furnish the compound 17. Deprotection of the acetal under standard conditions followed by Method C gives 18.
Method E
Alcohol 16 is converted to an acetate with acetyl chloride (or acetic anhydride and an amine base) and coupled with a Grignard reagent and a copper salt at low temperature. The alcohol 16 could also be converted to the bromide and treated in a similar way to yield 20. Alternatively the tetrametyl acetal (R= methyl) version of alcohol 16 can be treated with TiCl4/Me2Zn (or R7 2Zn) at -30 °C. Compound 20 is then converted to the cinnamic sulfonamide 21 according to Method D. Also, 22 can be treated with A1(R7)3 in toluene at 80 °C for 24h and 23 converted to the aldehyde with n-BuLi/DMF followed by an Emmons-Horner reaction and Method A to yield compound 21.
Method F
A suitably substituted bromo toluene 24 is treated with n- Buli at low temperature and quenched with an aryl or heteroaryl aldehyde. The resulting alcohol is oxidized to the ketone with PDC, PCC, Mn02 or other typical oxidizing agent. The carbonyl is treated with SF4, MoF6-BF3 (or converted to a thioacetal and treated with nitrosonium BF4- pyridinium*HF) to yield the difluoride. Benzylic bromination with NBS followed by oxidation with N-methylmorpholine N-oxide at 100 °C in dioxane for 4 h, yielded compound 25 that is converted to cinnamic sulfonamide 26 with Method C.
Method G
The appropriately substituted methyl bromo(or triflate) benzoate 27 is converted to compound 28 by a Suzuki coupling reaction followed by hydrogenation. A Stille coupling reaction could also be used. Benzylic bromination or benzylic oxidation followed by treatment with a brominating agent such as CBr4/triphenylphosphine gives compound 29 which can be treated with a boronic acid, or a tin compound (Stille) to furnish compound 30. Reduction of the ester with DIBAL, oxidation with Mn02 and Method C gives compound 31.
Method H
Compound 29 (one R7 = H) is treated with triphenyl phosphine to give the salt and, with a base such as LDA, is converted to compound 32 with the aryl or heteroaryl ketone. The halide 29 can also be converted the Grignard reagent and added to the ketone. Dehydration under acidic conditions results in compound 32. Reduction of the double bond under standard conditions, followed by Methods G and C gives compound 33. From compound 32, cyclopropanation with diazomethane and palladium (0) followed by Methods G, C and A gives compound 34.
Method I
The (heterocyclic) vinylic bromide 35 is reacted in a Suzuki coupling reaction with an aryl or hetero aryl boronic acid and converted to a new borane by 9-BBN addition followed by a second Suzuki reaction with compound 14. Compound 37 thus formed is reduced by hydrogenolysis ( H^metal or diimide) and deprotection followed by Method C gives cinnamic sulfonamide 39.
Method J
Ketone 40 which comes from oxidation of the corresponding alcohol is reacted with a phosphonium salt or phosphono ester with a base such as LDA to give the cinnamic ester 41. Method A yields 42 and reduction of the double bond by the previously mentioned method gives the acyl sulfonamide 43.
Method K
Cinnamic ester 3 is reduced to 44 by the previously mentioned method, α Alkylation with a base such as LDA followed by an alkylating agent results in 45 after conversion to the acyl sulfonamide.
Method L
Cinnamic ester 3 is reduced to 46 with DIBAL and the double bond converted to a cyclopropane by a Simmons-Smith reaction, or similar reactions recently described in the literature. Compound 47 is then oxidized and the cinnamic sulfonamide 48 is prepared according to Method A.
Method M
Ester 49 which can come from the homologation of the appropriately substituted methyl ortho-toluate, is treated with a base and with an alkylating agent to furnish compound 50. Benzylic bromination and Suzuki coupling gives an intermediate ester. Homologation according to J. Amer. Chem. Soc; 1985, 1429; J. Org. Chem. 1992, 7194, followed by alkylation with a base such as LDA and an alkylating agent furnishes acylsulfonamide 51 by Method A.
Compound 50 can also be converted to the benzylic bromide and to compound 52 by Method A.
Method N
Suitably substituted compound 53 is treated with a boronic acid to give compound 54 which is reduced with LDA to the alcohol 55. Treatment with phosgene followed with the appropriate sulfonamide gives compound 56. This can also be prepared by mixing phosgene and the sulfonamide at 140°C to generate the isocyanate.
Compound 54 is treated with a Grignard reagent to give the corresponding alcohol and as previously described, converted to compound 57.
Method O
Ester 58 is treated with Lawesson's reagent, DAST and light to give the benzylic alcohol 59. The procedure according to Method N yields compound 60.
Method P
Compound 59 is brominated as described earlier (or iodinated) and reacted in a SN2 type reaction with an ester and a base such as LDA to furnish ester 61. Method A gives the acylsulfonamide
62.
Method Q
Compound 55 is treated with NH3/Ph3P/DEAD (or treated with CBr4/Ph3P and the bromide converted to the amine 63 with ammonia). Treatment with phosgene followed by sulfonamide yields 64, treatment of which with a base and an alkyl or benzylic halide gives compounds 65.
Method R Aldehyde 10 is treated with a silylated source of hydroxyl or thiol at 80-130 °C, and the silyl group removed by fluoride treatment. Compound 66 is then treated with an aryl or heteroaryl methylene bromide with a base such as a tertiary amine in CHC13 or benzene to yield aldehyde 67. Emmons-Horner (or Wittig reaction) with LDA results in compound 68 via Method A.
Method S
In the case of an amine an alternative to method R can be used. A suitably substituted nitro aldehyde 69 is converted to compound 70 as described earlier and the nitro group reduced with standard methods. Mono-alkylation followed by displacement with an aryl or heteroaryl methylene bromide and processing by Method A yields cinnamic sulfonamide 71.
Method T
A suitably substituted bromo toluene 24 is converted to the anion in an etheral solvent at low temperature and trapped with an aldehyde of an aryl or heteroaryl. The resulting alcohol is oxidized with Mn02, Jones' reagent, PDC, PCC or any other oxidant. Benzylic bromination followed by oxidation with N-methyl morpholine N-oxide, yields a ketoaldehyde. Emmons-Horner and Method A gives the cinnamic sulfonamides 72.
Generic structures 4, 5, 7, 9, 13, 18, 21, 26, 31, 33, 34, 39, 42, 43, 45, 48, 51, 52, 56, 57, 60, 62, 64, 65, 68, 71 and 72 are representative of the compounds of the present invention. It is also noted that where the chemistry allows in the generic schemes, alternate embodiments of -A-, such as heteroaryl groups, can be substituted for phenyl in the schemes. Method A
Figure imgf000054_0001
Hydrolysis
Figure imgf000054_0002
Figure imgf000054_0003
Method B
Figure imgf000055_0001
Method A
Figure imgf000055_0002
Method C
Figure imgf000055_0003
10 11
Method B
Figure imgf000055_0004
Figure imgf000055_0005
Method D
Figure imgf000056_0001
R= H, Methyl
Figure imgf000056_0002
Method E
Protection
Figure imgf000057_0001
Figure imgf000057_0002
Figure imgf000057_0004
Figure imgf000057_0003
Method F
Figure imgf000058_0001
Figure imgf000058_0002
Method C, A
Figure imgf000058_0003
Method G
Figure imgf000059_0001
Method C, A
Figure imgf000059_0002
Method H
Figure imgf000060_0001
Method
Figure imgf000060_0002
1-[Red]
2- Hydrolysis
Method C,A
Figure imgf000060_0004
Figure imgf000060_0003
Method J
Figure imgf000061_0001
Method A NHS02R 19 [Red]
Figure imgf000061_0002
Figure imgf000061_0003
Method K
Figure imgf000061_0004
Figure imgf000061_0005
Method L
Reduction
Figure imgf000062_0001
Figure imgf000062_0002
od A
Figure imgf000062_0003
Figure imgf000062_0004
Method M
Figure imgf000063_0001
Homologation
Figure imgf000063_0002
Method N
Figure imgf000064_0001
Method O
Figure imgf000065_0001
Figure imgf000065_0002
Method P
Bromination
Figure imgf000066_0001
Figure imgf000066_0002
Method A
Figure imgf000066_0003
Method Q
Figure imgf000067_0001
Figure imgf000067_0002
Method R
Figure imgf000068_0001
68
Method S
Figure imgf000069_0001
70
69
Figure imgf000069_0002
Method T
Figure imgf000070_0001
B HET
Figure imgf000070_0002
ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY
Biological activity and thus utility for the compounds of formula I as modulators of prostaglandin mediated diseases can be demonstrated in accordance with the following assayswhich demonstrate prostanoid antagonist or agonist activity in vitro and in vivo and their selectivity. The prostaglandin receptors investigated were DP, EP EP2, EP3, EP4, FP, IP and TP.
Stable expression of prostanoid receptors in the human embryonic kidnev (HEK) 293(ebna) cell line Prostanoid receptor cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells. HEK 293(ebna) cells expressing the individual cDNAs were grown under selection and individual colonies were isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.
Prostanoid receptor binding assays
HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays. Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the appropriate radioligand. The reaction is initiated by addition of membrane protein. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 1 μM of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand affinity.
Prostanoid receptor agonist and antagonist assays
Whole cell second messenger assays measuring stimulation (EP2, EP4, DP and IP in HEK 293(ebna) cells) or inhibition (EP3 in human erythroleukemia (HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EP1? FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or antagonists. For cAMP assays, cells are harvested and resuspended in HBSS containing 25 mM HEPES, pH 7.4. Incubations contain 100 μM RO-20174 (phosphodiesterase type rV inhibitor, available from Biomol) and, in the case of the EP3 inhibition assay only, 15 μM forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP levels are then measured. For calcium mobilization assays, cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and both EC50 values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both KB and slope values are calculated.
Rat Paw Edema Assay
The method is the same as described in Chan et al (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
LPS-Induced Pyrexia in Conscious Rats
The method is the same as described in Chan et al (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).
LPS-Induced Pyrexia in Conscious Squirrel Monkeys
The method is the same as described in Chan et al (Eur. J. Pharmacol. 327: 221- 225, 1997).
Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats The method is the same as described in Boyce et al (Neuropharmacology 33: 1609-1611, 1994). Adjuvant-Induced Arthritis in Rats
Female Lewis rats (body weight -146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of Mycobacterium butyricum in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.
The invention is illustrated in connection with the following non-limiting Examples. All the end products of the formula I were analyzed by NMR, TLC and mass spectrometry. Intermediates were analyzed by NMR and TLC.
Most compounds were purified by flash chromatography on silica gel. Recrystallization and/or swish (suspension in a solvent followed by filtration of the solid) with a solvent such as ether :hexane 1:1. The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only.
Temperatures are in degrees Celsius. The compounds of the examples are numbered in accordance with the compounds that appear in Tables I and II.
EXAMPLE 1
N-((E)-3-{2-[4-(METHYLTHIO)BENZYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (17)
Step 1: Methyl (E)-3-(2-methvk>henyl)-2-propenoate
To 2-methylcinnamic acid (lOOg; 617 mmol) in 1.2 L of DMF was added DBU (112.6 g; 740 mmol) and 15 min later methyl iodide (131.3 g; 925 mmol) and left overnight. The solution was diluted in ether and washed with HC1 (10%), H20 and brine. The solvent was removed to give 106.8 g of the title compound.
Η NMR (CDClg) δ 2.4 (3H, s), 3.8 (3H, s), 6.35 (1H, d), 7.15 (1H, t), 7.22 (1H, t), 7.5 (1H, d) and 7.95 (1H, d).
The ethyl ester can be prepared as well in the same way or from the 2-methyl benzaldehyde ( 5.00 g; 41.6 mmol) and triethyl phosphonoacetate (9.9 mL; 50.0 mmol) in 150 mL ot toluene at 0 CC, to which was added portionwise NaH (63.0 mmol). After 2 h of stirring the mixture was quenched with NH4OAc (25%) and extracted with EtOAc. The solvent was removed to give 7.1 g of the ethyl cinnamate. Step 2: Ethyl (E)-3-.2-(bromomethyl)phenyl1-2-propenoate
To the previous ethyl cinnamate (20.0 g; 105 mmol) and NBS (19.64 g; 110.3 mmol) in refluxing CC14 was added benzoyl peroxide (1.27 g) and the mixture was stirred for 12 h. The solution was cooled to r.t. and filtered. The solvent was removed and the crude oil purified by silica gel chromatography (5% EtOAc in hexane) to yield 14.18 g of the title compound.
Η NMR (CDC13) δ 1.30 (3H, t), 4.25 (2H, q), 4.60 (2H, s), 6.45 (1H, d), 7.30 (3H, m), 7.57 (1H, m) and 8.05 (1H, d).
Step 3: Ethyl (E)-3-(2-.4-(methylthio)benzvHphenyl.-2-propenoate A mixture of the previous benzyl bromide (0.50 g; 1.86 mmol), 4-(methylthio)benzeneboronic acid (0.63 g; 3.7 mmol) CsF (1.13 g) and ( Ph3P)4Pd (0.11 g) in 10 mL of DME was heated to reflux for 10 h. The mixture was cooled to r.t. and quenched with NH4OAc (25%) and extracted with EtOAc. The organic phases were combined, dried and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 0.35 g of the title compound.
Η NMR (CDC13) δ 1.27 (3H, t), 2.41 (3H, s), 4.08 (2H, s), 4.21 (2H, q), 6.30 (1H, d), 7.00 (1H, d), 7.1-7.4 (6H, m), 7.55 (1H, d) and 7.97 (1H, d).
Step 4: (E)-3-{2- 4-Methylthio)benzyllphenyll-2-propenoic acid
Hydrolysis of the previous ester (0.34 g; 1.1 mmol) was run in THF/MeOH (6 mIV3 mL) with 2 equivalent of a 2N NaOH solution for 4 h. The solution was diluted with EtOAc and quenched with HCl (10%). The organic phase was dried over Na2S04 and the solvent removed. Purification was done by a swish in hexane to yield 0.21 g of the title compound.
Η NMR (CDC13) δ 2.42 (3H, s), 4.09 (2H, s), 6.31 (1H, d), 7.00- 7.35 (7H, m), 7.50 (1H, d) and 8.07 (1H, d).
Step 5: N-((E)-3-f2-.4-(methylthio)benzyllphenyl}-2-propenoyl)-2- thiophenesulfonamide (17)
2-Thiophenesulfonamide was prepared from the corresponding sulfonyl chloride with 2.2 equivalent of NH4OH in THF at 0 °C. The solution was brought to r.t. and left 2 h. It was then quenched with NaHC03 and extracted with EtOAc. The organic phase was dried over Na2SO4 and the solvent removed. The crude product was crystallized in toluene/EtOAc. To the previous acid (100 mg; 0.35 mmol), 2- thiophenesulfonamide (60 mg; 0.37 mmol), DMAP (86 mg; 0.7 mmol) in 2 mL of CH2C12 was added DCI (134 mg; 0.7 mmol) and the mixture was stirred overnight. The solution was diluted with EtOAc and quenched with HCl (10%). The organic phase was dried over Na2S04 and the solvent removed. Purification by silica gel chromatography (5% MeOH in CH2C12) yielded 87 mg of the title compound.
Η NMR (CDC13) δ 2.40 (3H, s), 4.01 (2H, s), 6.33 (1H, d), 6.9- 7.3 (8H, m), 7.49 (1H, d), 7.61 (1H, s), 7.89 (1H, s) and 8.03 (1H, d). The product was converted to the sodium salt with 1 equivalent of NaOH and freeze dried.
Elemental analysis calcd. for C21H18NNa03S3.l/2H20: C, 54.77; H, 4.13; N, 3.04; S, 20.88; Found: C, 54.55; H, 4.01; N, 3.06; S, 20.58.
EXAMPLE 2
N-((E)-3-{2-[(3-METHYL-lH-l-INDOLYL)METHYL]PHENYL}-2- PROPENOYL)-2-THIOPHENESULFONAMIDE (3)
Step 1: Ethyl (E)-3-{2-r(3-methyl-lH-l-indolyl)methvnphenyll-2- propenoate
To benzylic bromide (400 mg, 1.49 mmol) of step 2 in example 1 and skatole (200mg, 1.51 mmol) in 6 mL of DMF was added portionwise 1.6 equivalent of NaH. The reaction mixture was left for 6 h and quenched with NH4OAc (25%) and diluted with EtOAc. The organic phase was dried over Na2S04, filtered and the solvent removed.
Purification by silica gel chromatography (10% EtOAc inhexane) yielded
260mg of the title compound.
Η NMR (CDC13) δ 1.2 (3H, t), 2.3 (3H, s), 4.25 (2H, q), 5.4 (2H, s), 6.35 (1H, d), 6.65 (1H, d), 6.8 (1H, s), 7.1-7.3 (5H, m), 7.56 (2H, d) and 7.97 (1H, d).
Step 2: (E)-3-.2-.(3-methyl-lH-l-indolyl)methyl1phenyl}-2-propenoic acid
The hydrolysis of the previous ester (260 mg) was done according to Step 4 of example 1 to yield 212 mg of the title compound. HRMS calcd. for C19H17N03 + H+ = 292.1337; Found:
292.1337.
Step 3: N2-((E)-3-f2-r(3-methyl-lH-l-indolyl)methvnphenyll-2-propenoyl)- 2-thiophenesulfonamide (3) The coupling reaction of the previous acid (196 mg; 0.67 mmol) was done according to step 5 of example 1 to yield 134 mg of the title compound.
Η NMR (acetone-d6) δ 2.39 (3H, s), 5.57 (2H, s), 6.65 (2H, m), 7.03 (3H, m), 7.27 (4H, m), 7.5 (IH, d), 7.63 (IH, d), 7.87 (IH, d), 7.95 (IH, s) and 8.14 (IH, d).
HRMS calcd. for C23H20N2O3S2 + H+= 437.0994; Found: 437.0992.
EXAMPLE 3 N-{(E)-3-[2-(2-NAPHTHYLMETHYL)PHENYL]-2-PROPENOYL}-2-
THIOPHENESULFONAMIDE (4)
Step 1: Ethyl (E)-3-r2-(2-naphthylmethyl)phenyl1-2-propenoate
The benzyl bromide (500 mg) of example 1, step 2 was treated with 2-naphthylboronic acid according to the same procedure previously described to yield 360 mg of the title compound.
Η NMR (CDC13) δ 1.30 (3H, t), 4.27(2H, q), 4.33 (2H, s), 6.48 (IH, d), 7.2-7.4 (4H, m), 7.45 (2H, m), 7.55 (IH, s), 7.62 (IH, d), 7.8 (3H, m) and 8.15 (IH, d).
Step 2: (E)-3-f2-(2-naphthylmethyl)phenvn-2-propenoic acid
The hydrolysis of the previous ester (300 mg) was done according to Step 4 of example 1 to yield 202 mg of the title compound. Η NMR (CDCI3) δ 4.29 (2H, s), 6.32 (IH, d), 7.2-7.4 (6H, m), 7.5 (IH, s), 7.62 (IH, d), 7.73 (3H, m) and 8.19 (IH, d).
Step3: N-((E)-3-.2-(2-naphthylmethyl)phenyll-2-propenoyll-2- thiophenesulfonamide (4)
The coupling reaction of the previous acid (100 mg; 0.35 mmol) was done according to step 5 of example 1 to yield 60 mg of the title compound.
Η NMR (CDCI3) δ 4.24 (2H, s), 6.31 (IH, d), 7.02 (IH, m), 7.15-7.8 (12H, m), 7.84 (IH, m) and 8.08 (IH, d). The acid was converted to the sodium salt with 1 equivalent of NaOH.
Elemental analysis calcd. for C24H18NNa03S2.H20: C, 60.87; H, 4.22; N, 2.96; S, 13.54; Found: C, 60.36; H, 4.25; N, 3.29; S, 12.53.
EXAMPLE 4
N-{(E)-3-[2-(3,4-DICHLOROBENZYL)PHENYL]-2-PROPENOYL}-2- THIOPHENESULFONAMIDE (8)
Step 1: Ethyl (E)-3-r2-(3.4-dichlorobenzyl)phenyl1-2-propenoate The benzyl bromide (500 mg) of example 1, step 2 was treated with 3,4-dichlorobenzeneboronic acid according to the same procedure described in step 3 of example 1 to yield 410 mg of the title compound.
Η NMR (CDC13) δ 1.30 (3H, t), 4.03 (2H, s), 4.23 (2H, q), 6.28 (IH, d), 6.90 (IH, dd), 7.1-7.4 (5H, m), 7.57 (IH, d) and 7.89 (IH, d).
Step 2: (E)-3-.2-(3.4-dichlorobenzyl)phenyri-2-propenoic acid
The hydrolysis of the previous ester (400 mg) was done according to Step 4 of example 1 to yield 296 mg of the title compound. Η NMR (CDC18) δ 4.07 (2H, s), 6.31 (IH, d), 6.93 (IH, dd), 7.1-
7.4 (5H, m), 7.50 (IH, d) and 7.99 (IH, d).
Step 3: N-{(E)-3-.2-(3.4-dichlorobenzyl)phenvn-2-propenoyl.-2- thiophenesulfonamide (8) The coupling reaction of the previous acid (170 mg; 0.55 mmol) was done according to step 5 of example 1 to yield 110 mg of the title compound.
Η NMR (CDCI3) δ 4.07 (2H, s), 6.33 (IH, d), 6.85 (IH, d), 7.07 (3H, m), 7.24 (2H, m), 7.32 (IH, t), 7.53 (IH, d), 7.63 (IH, d), 7.88 (IH, d) and 7.97 (IH, d).
The acid was converted to the sodium salt with 1 equivalent of NaOH.
Elemental analysis calcd. for C20H14Cl2NNaO3S2.l/2H2O: C, 49.7; H, 3.1; N, 2.9; S, 13.27; Found: : C, 49.46; H, 2.9; N, 2.86; S, 13.73; EXAMPLE 5
N-((E)-3-{2-[(2-NAPHTHYLOXY)METHYL]PHENYL}-2-PROPENOYL)-2-
THIOPHENESULFONAMIDE (20)
Step 1: Ethyl (E)-3-{2-.naphthyloxy)methyriphenyl.-2-propenoate The benzyl bromide (250 mg, 0.93 mmol) of step 2 in example
1 and 2-naphthol (147 mg) in 5 mL of DMF were treated with cesium carbonate (394 mg) at 40 °C for 12 h. The mixture was diluted with
EtOAc and washed with water and brine. The organic phase was dried over Na2S04, filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 245 mg of the title compound.
Η NMR (CDClg) δ 1.2 (3H, t), 4.22 (2H, q), 5.28 (2H, s), 6.41
(IH, d), 7.22 (2H, m), 7.3-7.5 (4H, m), 7.55 (IH, m), 7.64 (IH, m), 7.75 (3H, m) and 8.05 (IH, d).
Step 2: (E)-3-.2-.naphthyloxy)methyl1phenyl}-2-propenoic acid
Hydrolysis of the previous ester (245 mg, 0.74 mmol) was done according to step 4 of example 1 to yield 185 mg of the title compound. Η NMR (CDC13) δ 5.27 (2H, s), 6.45 (IH, d), 7.15-7.25 (2H, m),
7.32 (IH, t), 7.42 (3H, m), 7.55 (IH, d), 7.67 (IH, d), 7.77 (3H, ) and 8.11
(IH, d).
Step 3: N-((E)-3-!2-.(2-naphthyloxy)methyllDhenyl)-2-propenoyl)-2- thiophenesulfonamide (20)
The coupling reaction of the previous acid (150 mg; 0.49 mmol) was done according to step 5 of example 1 to yield 77 mg of the title compound.
Η NMR (CDCI3) δ 5.2 (2H, s), 6.39 (IH, d), 7.02 (IH, s), 7.1- 7.2 (2H, m), 7.3-7.4 (4H, m), 7.53 (3H, ), 7.71 (3H, m), 7.83 (IH, s) and 8.07 (IH, d).
The product was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C24H28NNa04S2.3/2H2O: C,
57.82; H,4.21; N, 2.81; Found: : C, 58.31; H, 3.96; N, 2.91.
EXAMPLE 6 N-{(E)-3-[2-(2-NAPHTHYLSULFINYL)PHENYL]-2-PROPENOYL}-2- THIOPHENESULFONAMIDE (21)
Step 1: 2-(2-naphthylthio)benzaldehyde
A mixture of 2-thionaphthol (5.29 g; 33 mmol), 2- fluorobenzaldehyde (3.73 g; 33 mmol) and potassium carbonate (4.57 g; 33 mmol) in 28 mL of iso-propanol was heated to reflux for 12 h. The mixture was cooled to r.t., diluted with water and filtered. The solution was diluted with EtOAc and washed with water, brine and dry over MgS04. The crude product (7.9 g) was used as is for the next step.
Η NMR (CDC13) δ 7.07 (IH, d), 7.32 (2H, m), 7.42 (IH, d), 7.51 (2H, m), 7.78 (IH, m), 7.83 (2H, d), 7.88 (IH, s), 7.95 (IH, s) and 10.39 (IH, s).
Step 2: Ethyl (E)-3-.2-(2-naphthylthio)phenyll-2-propenoate
The previous aldehyde (7.72 g; 29.2 mmol) was converted to the ethyl ester according to step 1 of example 1 to furnish 6.36 g of the title compound.
Η NMR (CDClj) δ 1.24 (3H, t), 4.21 (2H, q), 6.36 (IH, d), 7.28 (4H, ), 7.42 (2H, m), 7.61 (IH, d), 7.72 (4H, m) and 8.28 (IH, d).
Step 3: Ethyl (E)-3-.2-(2-naphthylsulfinyl)phenyll-2-propenoate The previous ester (3.00 g; 8.97 mmol) in 45 mL of dichloromethane was treated with 1.1 equivalent of mCPBA at 0 °C for 1 h. The mixture was quenched with sodium thiosulfϊte and extracted with EtOAc. The organic phase was dry over Na2S04 and the crude purified by silica gel chromatography (30% EtOAc in hexane) to yield 2.35 g of the title compound.
Η NMR (CDC13) δ 1.34 (3H, t), 4.27 (2H, q), 6.26 (IH, d), 7.42 (2H, m), 7.53 (4H, m), 7.77 (2H, m), 7.88 (2H, m), 8.07 (2H, d), 8.22 (IH, s) and 8.28 (2H, m). Step 4: Ethyl (E)-3-.2-(2-naphthylsuIfinyl)phenyri-2-propenoic acid The previous ester (1.20 g; 3.43mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.08 g of the title compound. Η NMR (methanol-d6) δ 6.23 (IH, d), 7.33 (IH, dd), 7.45 (3H, ), 7.53 (IH, t), 7.62 (IH, d), 7.8 (3H, m), 7.98 (IH, d), 8.05 (IH, d) and 8.27 (IH, s).
Step 5: 2-!(E)-3-r2-(2-naphthylsulfinyl)phenyl1-2-propenoyl.-2- thiophenesulfonamide (21)
The coupling reaction of the previous acid (500 mg; 1.55 mmol) was done according to step 5 of example 1 to yield 416 mg of the title compound.
Η NMR (methanol-d6) δ 6.19 (IH, d), 7.1 (IH, m), 7.22 (IH, dd), 7.45 (3H, m), 7.55 (2H, m), 7.67 (IH, d), 7.72-7.85 (4H, m), 7.99 (IH, d), 8.1 (IH, d) and 8.17 (IH, s).
The sodium salt was prepared with IN NaOH. Elemental analysis calcd. for C23H16NNa04S3.l/2H20: C, 55.36; H,3.40; N, 2.81; S,
19.27; Found: : C,55.00; H, 3.62; N, 2.81; S, 18.18.
EXAMPLE 7
N-{(E)-3-[2-(2-NAPHTHYLOXY)PHENYL]-2-PROPENOYL}-2-
THIOPHENESULFONAMIDE (28)
Step 1: Ethyl (E)-3-.2-(2-naphthyloxy)phenyll-2-propenoate
2-fluoro benzaldehyde (3.0 g; 24.2 mmol), 2-naphthol (24.2 mmol) and potassium carbonate (26.6 mmol) were heated at reflux in dimethyl acetamide for 2 h. The mixture was cooled to r.t., diluted with EtOAc and washed with water and brine. The organic phase was dried over Na2S04, filtered and the solvent removed. Purification by silica gel chromatography (10% EtOAc in hexane) yielded 3.4 g of the title compound. Η NMR (CDCI3) δ 6.93 (IH, d), 7.17-7.23 (IH, m), 7.28 (IH, dd), 7.37 (IH, s), 7.37 (3H, m), 7.7 (IH, d), 7.84 (2H, m), 7.94 (IH, d) and 10.53 (IH, s).
Step 2: Ethyl (E)-3-r2-(2-naphthyloxy)phenyll-2-propenoate The previous aldehyde (2.00 g; 8.0 mmol) was converted to the title compound according to step 1 of example 1 to yield 2.52 g .
Η NMR (CDCI3) δ 1.25 (3H, t), 4.21 (2H, q), 6.55 (IH, d), 6.9
(IH, d), 7.15 (IH, t), 7.25 (3H, m), 7.42 (2H, m), 7.65 (2H, m), 7.83 (2H, t) and 8.02 (IH, d).
Step 3: (E)-3-l2-(2-naphthyloxy)phenyll-2-propenoic acid
The previous ester (2.52 g; 7.9 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 1.57 g of the title compound. Η NMR (CDCI3) δ 6.62 (IH, d), 7.03 (IH, d), 7.2-7.5 (6H, m),
7.78 (IH, d) and 7.88-8.03 (4H, m). HRMS calcd. for C19H1403 + H+ =
291.1021; Found: 291.1022.
Step 4: N-.(E)-3-.2-(2-naphthyloxy)phenyl.-2-propenoyl)-2- thiophenesulfonamide (28)
The coupling reaction of the previous acid (1.00 g; 3.4 mmol) was done according to step 5 of example 1 to yield 790 mg of the title compound.
Η NMR (CDCI3) δ 6.91 (IH, d), 6.97 (IH, d), 7.15(1H, dd), 7.24 (IH, t), 7.29 IH, dd), 7.37 (IH, d), 7.40-7.55 (3H, m), 7.74-7.83 (2H, m), 7.92 (2H, m) and
7.99 (2H, m).
The sodium salt was prepared with IN NaOH. HRMS calcd. for C23H16NNa04S2 + H+ = 458.0497; Found:458.0497.
EXAMPLE 8
THIOPHENE-2-SULFONYL CARBAMIC ACID [2-(2- NAPHTHYLSULFONYDPHENYL1 METHYL ESTER (31)
Step 1: [2-(2-naphthylthio)phenynmethanol To 2-(2-naphthylthio) benzaldehyde (7.24 g; 27.4 mmol from
Example 6, step 1) in 70 mL of methanol and 30 mL of THF at 0 °C was added NaBH4 (54.8 mml) portionwise. After lh at 0 °C, the solution was brought to r.t. and quenched with water. After dilution with EtOAc, the solution was washed with water and brine. The organic phase was dry over Na2S04, filtered and the crude purified by silica gel chromatography to yield 6.71 g of the title compound.
Η NMR (acetone-d6) δ 4.29 (IH, t), 4.7 (2H, d), 7.29 (2H, m), 7.35-7.52 (4H, m), 7.71 (2H, m), 7.77 (IH, m) and 7.83 (2H, m).
Step 2: .2-(2-Naphthylsulfonyl)phenyll methanol
To the previous sulfide (500 mg; 1.88 mmol) in 8 mL of dichloromethane at 0 °C was added m-CPBA (5.64 mmol) and let stirred for 2 h. The mixture was diluted with EtOAc and washed with NaOH (IN) and brine. The organic phase was dry over Na2S04, filtered and the crude purified by silica gel chromatography (40% EtOAc in hexane) to yield 390 mg of the title compound.
Η NMR (acetone-d6) δ 4.37 (IH, t), 4,9 (2H, d), 7.57 (IH, dt), 7.65-7.80 (4H, m), 7.82 (IH, d), 8.0-8.1 (2H, m), 8.2 (2H, m) and 8.63 (IH, s).
Step 3: 2-Thiophenesulfonyl isocvanate
A mixture of 2-thiophenesulfonylamide (1.5 g) and oxalyl chloride (6 mL) in 10 mL of 1,2-dichloroethane was refluxed for 14h. The solvent was removed under vacuum and the crude used as is for the next step.
Step 4:
To the alcohol of step 2 (250 mg; 0.84 mmol) in ether at 0 °C was added the previous isocyanate (2 equivalent) and let stirred lh at 0 °C. The solution was quenched with water and extracted with EtOAc. The organic phase dry over Na2S04, filtered and the crude purified by silica gel chromatography (5% CH3OH in CH2C12) to yield 300 mg of the title compound. Η NMR (CDC13) δ 5.55 (2H, s), 7.08 (IH, m), 7.55-7.72 (6H, m), 7.82 (2H, m), 8.0 (IH, d), 8.07 (IH, d), 8.2 (2H, m) and 8.66 (IH, s). The sodium salt was prepared with IN NaOH. Elemental analysis calcd. for C22H16NNa06S3.2H20: C, 48.44; H,3.67; N, 2.57; S, 17.63; Found: : C.48.86; H, 3.13; N, 2.63; S, 16.46.
EXAMPLE 9
N-({2-[2-(2-NAPHTHYLMETHYL)PHENYL]CYCLOPROPYL} CARBONYL-2-THIOPHENESULFONAMIDE (45)
Step 1: Ethyl 2-f2-(2-naphthylmethyl)phenyll-l-cyclopropanecarboxylate The ethyl ester (300 mg; 0.95 mmol) of step 1 in example 3 and Pd(OAc)2 (10 mg) were treated with diazomethane at 0° C for lh.
The solvent was removed and the crude oil purified by silica gel chromatography (5% EtOAc in hexane) to yield 300 mg of the title compound. Η NMR (CDClg) δ 1.1 (3H, t), 1.27 (IH, m), 1.45 (IH, m), 1.7
(IH, m), 2.53 (IH, m), 3.98 (2H, m), 4.29 (2H, s), 7.0 (IH, m), 7.18 (3H, m),
7.27 (IH, m), 7.39 (2H, m), 7.48 (IH, s) and 7.75 (3H, m).
Step 2: 2-.2-(2-naphthylmethyl)phenyl.-l-cyclopropanecarboxylic acid The previous ester (300 mg; 0.91 mmol) was hydrolyzed according to the procedure of step 4 of example 1 to yield 230 mg of the title compound.
Η NMR (CDClg) δ 1.45 (IH, m), 1.6 (IH, m), 1.8 (IH, m), 2.67
(IH, m), 4.33 (2H, s), 7.1 (IH, m), 7.24 (4H, m), 7.41 (2H, m), 7.58 (IH, s) and 7.78 (3H, m).
Step 3: N-((2-.2-(2-naphthylmethyl)phenyllcyclopropyl.carbonyl-2- thiophenesulfonamide (45)
The coupling reaction of the previous acid (230 mg; 0.76 mmol) was done according to step 5 of example 1 to yield 100 mg of the title compound.
Η NMR (CDCI3) δ 1.32 (IH, m), 1.48 (IH, m), 1.63 (IH, m),
2.6 (IH, m), 4.13 (2H, s), 6.97 (2H, m), 7.12 (4H, m), 7.38 (3H, m), 7.52 (IH, d), 7.65 (2H, m) and 7.79 (2H, m). The sodium salt was prepared with IN NaOH. Elemental analysis calcd. for C25H20NNaO3S2.l/2H2O: C, 62.75;
H, 4.39; N, 2.93; S, 13.4; Found: : C,62.25; H, 4.24; N, 3.02; S, 12.15. EXAMPLE 10
N-((E)-3-(2-(6-BENZYLOXY-2-NAPHTHYL)METHYL)PHENYL)-2- PROPENOYL)-5-BROMO-2-METHOXYBENZENESULFONAMIDE (46)
(E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoic acid Step 1: ■(6-bromo-2-naphthyl)oxyKphenyl)methane
To a mixture of 6-bromo-2-naphthol (1.99 g, 8.9 mmol) and benzyl bromide (1.2 ml, 1.1 equiv.) in DMF (18 ml) at 0°C was added a suspension of NaH 80% in oil (324 mg, 1.2 equiv.) and the mixture was stirred at 0°C for an hour and at r.t. for another hour. After addition of half saturated NH4C1, the product was extracted in i-PrOAc, washed with 1 N HCl, dried over Na2S04 and concentrated to yield 2.84 g of an oil.
Step 2: 6-benzyloxy-2-naphthaleneboronic acid
To a solution of the previous bromide (940 mg, 3.00 mmol) in THF (15 ml) at -78°C was added n-BuLi 1.6 M in hexanes (2.2 ml, 1.2 equiv.) and the mixture was stirred at -78°C for 15 min. Tri-isopropyl borate (0.97 ml, 1.4 equiv.) was added and the reaction mixture was warmed to r.t. After addition of 2 N HCl, the product was extracted in EtOAc, dried over Na2S04 and concentrated to yield a solid. This solid was washed with ether:hexane 1:1 to yield 679 mg of pure material.
Η NMR (Acetone-d6:DMSO-d6) δ 5.27 (2H, s), 7.22 (IH, dd), 7.33 (IH, dd), 7.40 (3H, m), 7.54 (2H, d), 7.63 (2H, s), 7.72 (IH, d), 7.83 (IH, d), 7.90 (IH, d), 8.36 (IH, s).
Step 3: Ethyl (E)-3-(2-f ■6-benzyloxy)-2-naphthvHmethyl)phenyl)-2- propenoate
A mixture of the previous boronic acid (1.05 g, 3.8 mmol), Pd(Ph3P)4 (185 mg), the benzylic bromide of step 2 in example 1 (1.07 g, 4.0 mmol), 2 M aq. Na2C03 (4 ml) and toluene (8 ml) was degazed and stirred at 100° C under nitrogen for 4 h. After addition of half saturated NH4C1, the product was extracted in EtOAc, dried over Na2S04 and concentrated. Purification by flash chromatography with EtOAc:toluene:hexane 2.5:75:25 yielded 1.17 g of the title compound as an oil. Step 4: (E)-3-(2-(.6-(benzyloxy)-2-naphthyllmethyl.phenyl)-2-propenoic acid
The previous ester was hydrolyzed according to the procedure of step 4 of example 1 to yield the title compound.
Step 5: 5-Bromo-2-methoxybenzenesulfonamide
To 5-bromo-2-methoxybenzenesulfonyl chloride (45g; 157.6 mmol, from Lancaster Chemical) at 0°C in THF , was added concentrated NH4OH (42.5 mL) and the reaction mixture was brought to r.t. for 2 h. The reaction mixture was diluted with EtOAc, extracted with NaHCOg (2X), brine, and the organic phase was dried over MgS04. The solvent was removed to give the title compound.
Step 6: N-((E)-3-(2-(6-benzyloxy-2-naphthyl)methyl)phenyl)-2-propenoyl)- 5-bromo-2-methoxybenzenesulfonamide (46)
To the acid from step 5 (190 mg, 0.482 mmol) in CH2C12 was added DMF (10 μL) and oxalyl chloride (60 μL) at 0°C and the mixture was warmed to r.t. for an hour and concentrated to dryness. The resulting acid chloride was redissolved in CH2C12:THF 1:1 (10 mL) and 5- bromo-2-methoxybenzenesulfonamide (154 mg, 1.2 equiv., from step 6) and Et3N (135 μL, 2 equiv.) were added at 0°C. The mixture was then warmed to r.t. for an hour, 0.5 N HCl was added and the product was extracted in i-PrOAc, dried over Na2S04 and purified by flash chromatography with EtOAc: toluene: acetic acid 20:80:1 to yield 93 mg of a white solid.
Η NMR (CDClg) δ
MS (APCI, neg.) 643.3, 641.8, 640.0 (M-l), 393.2.
EXAMPLE 11 N-{(E)-3-[2-NAPHTHYLMETHYL)PHENYL)]-2-PROPENOYL}-5-
BROMO-2-METHOXY-l-BENZENESULFONAMIDE (301)
Step 1: N- ( (E)-3-f 2-naphthylmethyl)phenyl )1 -2-propenoyl }-5-bromo-2- methoxy-l-benzenesulfonamide (301) The carboxylic acid (400 mg; 1.22 mmol) of example 3 step 2 was coupled with 5-bromo-2-methoxy-l-benzenesulfonyl chloride according to the procedure of step 5 in example 1 to yield 284 mg of the title compound.
Η NMR (acetone-d6-DMSO-d6) δ 3.85 (3H, s), 4.31 (2H, s), 6.65 (IH, d), 7.15 (IH, d), 7.3 (IH, m), 7.35-7.50 (4H, m), 7.55-7.65 (2H, m),
7.7-7.9 (5H, m) and 8.01 (IH, d).
The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C27H21BrNNa04S.l/2H20: C,
57.15; H,3.88; N, 2.47; Found: : C, 56.88; H, 3.73; N, 2.52.
EXAMPLE 12
N-{(E)-3-[5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2-
PROPENOYLl-2-THIOPHENESULFONAMIDE (303)
Step 1: 5-chloro-2-methylbenzaldehyde
To a solution of 2-bromo-4-chlorotoluene ( 20.0 g; 97.3 mmol) in 300 mL of THF at -78 °C was added dropwise a 2.5 M solution of n-BuLi (102.2 mmol). After 30 min of stirring at that temperature, 1- formylpiperidine (11.4 mL) in 10 mL of THF was added and the solution left for 1 h. It was brought to 0 °C , quenched with NH4OAc (25%) and diluted with EtOAc. The organic phase was dried over Na2S04, filtered and the solvent removed to yield 13.3 g of the title compound.
Η NMR (CDClg) δ 2.6 (3H, s), 7.15 (IH, d), 7.4 (IH, d), 7.75 (IH, s) and 10.2 (IH, s).
Step 2: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate
The previous aldehyde (13.3 g; 86.0 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 16.67 g.
Η NMR (CDC13) δ 1.2 (3H, t), 2.26 (3H, s), 4.15 (2H, q), 6.21 (IH, d), 6.99 (IH, d), 7.13 (2H, m), 7.39 (IH, s) and 7.73 (IH, d).
Step 3: Ethyl (E)-3-[2-(bromomethyl)-5-chlorophenyll-2-propenoate The previous ester (16.66 g; 74.1 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 9.0 g of the title compound.
Η NMR (CDC13) δ 1,2 (3H, t), 4.25 (2H, q), 4.5 (2H, s), 6.4 (IH, d), 7.28 (2H, s), 7.55 (IH, s) and 7.95 (IH, d).
Step 4: Ethyl (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyri-2-propenoate
The previous benzylic bromide was coupled in a Suzuki type reaction with 2-naphthylboronic acid according to step 3 of example 1 to yield 1.14 g of the title compound. Η NMR (CDC18) δ 1.15 (3H, t), 4.09 (2H, q), 4.12 (2H, s), 6.2
(IH, d), 7.03 (IH, d), 7.15 (2H, m), 7.3 (2H, m), 7.37 (IH, s), 7.45 (IH, s), 7.65 (3H, m) and 7.87 (IH, d).
Step 5: (E)-3-[5-chloro-2-(2-naphthylmethyl)phenyll-2-propenoic acid The hydrolysis of the previous ester (1.14 g) was done according to Step 4 of example 1 to yield 0.99 g of the title compound.
Η NMR (CDCI3) δ 4.23 (2H, s), 6.31 (IH, d), 7.12 (IH, d), 7.22 (IH, m), 7.3 (IH, m), 7.42 (2H, m), 7.48 (IH, s), 7.59 (IH, s), 7.75 (3H, m) and 8.05 (IH, d).
Step 6: N-f(E)-3-l5-chloro-2-(2-naphthylmethyl)phenvn-2-propenoyl}-2- thiophenesulfonamide (303)
The coupling reaction of the previous acid (400 mg; 1.22 mmol) was done according to step 5 of example 1 to yield 272 mg of the title compound.
Η NMR (acetone-d6) δ 4.25 (2H, s), 6.58 (IH, d), 7.0 (IH, t), 7.23 (2H, m), 7.33 (IH, m), 7.39 (2H, m), 7.5-7.6 (2H, m), 7.55 (5H, m) 7.86 (IH, m) and 8.04 (IH, d).
The product was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for
C24H17ClNNa03S2.l/2H20: C, 57.76; H,3.64; N, 2.81; S, 12.84; Found: : C, 57.78; H, 3.62; N, 2.86; S, 12.85. EXAMPLE 13
(E)-3-{4-CHLORO-2-[6-FLUORO-2-NAPHTHYL)METHYL]PHENYL}-2- PROPENOIC ACID SODIUM SALT (457)
Step 1: Ethyl (E)-3-(5-chloro-2-methylphenyl)-2-propenoate To 2-bromo-4-chloro toluene (20.0g; 97.3 mmol) in 300 mL of THF at -78 oC was added n-BuLi 2.5 M (40.8 mL) dropwise. After 20 min. 1-formylpiρeridine (11.4 mL; 103.0 mmol) in 10 mL of THF was added dropwise. After 30 min the reaction mixture was brought to 0°C and quenched with HCl (10%) and diluted with EtOAc. The organic phase was collected, dry and the solvent evaporated to yield 13.3g (89%) of 5-chloro-2-methylbenzaldehyde. This crude aldehyde was mixed with 1.1 equivalent of tri ethyl phosphonoacetate in THF. Sodium hydride 80% (1.3 equivalent ) was added portionwise and 1 h later the reaction was quenched with 25% NH4C1. The reaction mixture was diluted with EtOAc and the organic phase collected, dried and the solvent removed. The crude oil was purified on a short pad of silica gel using 5% EtOAc in hexane to afford 16.67 g of the title compound.
Alternatively, this procedure can be done in one reaction vessel. At the end of the first step, the flask is brought to rt and the phosphonoacetate in THF is added.
IH NMR (CDC13) δ 1.21 (3H, t), 2.27 (3H, s), 4.15 (2H, q), 6.22 (IH, d), 6.95-7.15 (3H, m), 7.40 (IH, s) and 7.75 (IH, d).
Step 2: Ethyl(E)-3-.2-(bromomethyl)-5-chlorophenyll-2-propenoate The bromination was done according to step 2 of example 1 to provide the title compound in 45% yield.
Η NMR (CDC13) δ 1.32 (3H, t), 4.27 (2H, q), 4.52 (2H, s), 6.43 (IH, d), 7.30 (2H, s), 7.55 (IH, s) and 7.93 (2H, d).
Step 3: 6-Fluoro-2-naphthol
A solution of 2-(4-fluorophenyl)acetyl chloride (5.0g; 29 mmol) in CH2C12 was added to A1C13 (7.73g;58 mmol) in CH2C12 at -20 °C over 30 min. Trimethylsilyl acetylene (9.96g; 101.43 mmol) was added also over 30 min and stirred at -10 °C for lh. The mixture was poured in ice and extracted with EtOAc. The organic phase was washed with water, NaHC03 and brine. After purification by gel silica chromatography (10% EtOAc in hexane) 2.43 g (36%) of 3-(trimethylsilyl)- 6-chloro-2-naphthol was collected. The desylilation was done with TFA in CH2C12 at rt overnight. Purification by gel silica chromatography (10% EtOAc in hexane) afforded the title compound in 69% yield.
Η NMR (CDClg) δ 7.10-7.20 (3H, m), 7.37 (IH, dd) and 7.65 (2H, m).
Step 4: Ethyl (E)-3-{4-chloro-2-[(6fluoro-2-naphthyl)methyllphenyl)-2- propenoate
The naphthol of Step 3 was converted to the triflate with triflic anhydride/pyridine in CH2C12 at 0 °C. This was coupled with the organozinc of the benzyl bromide of step 2 in example 13, with dppf and Pd(dba)2. This yielded the title compound in 47% yield after purification by silica gel chromatography (10% EtOAc in hexane).
Η NMR (CDClg) δ 1.25 (3H, t), 4.20 (2H, q), 6.30 (IH, d), 7.10- 7.27 (4H, m), 7.38 (IH, dd), 7.48 (IH, s), 7.57 (IH, dd), 7.66 (2H, m) and 7.95 (IH, d).
Step 5: (E)-3-{4-Chloro-2- (6-fluoro-2-naphthyl)methyllphenyll-2- propenoic acid, sodium salt
The hydrolysis of the ester of Step 4 (1.03g; 2.7 mmol) was done according to step 4 of example 1 to yield 800mg (87%) of the title compound. The sodium salt was prepared with IN NaOH. IH NMR (CDC13) δ 4.21 (2H, s), 6.30 (IH, d), 7.10-7.40 (4H, m), 7.38 (IH, dd), 7.45 (IH, s), 7.58 (IH, d), 7.68 (2H, m) and 8.05 (IH, d). LRMS for M-l= 339.
EXAMPLE 14 5-BROMO-N((E)-3-{5-CHLORO-2-[(6-FLUORO-2-NAPHTHYL-
2)METHYL] PHENYL} -2-PROPENOYL)-2- METHOXYBENZENESULFONAMIDE SODIUM SALT (378) Step 1: 5-Bromo -N-((E)-3-f5-chloro-2-[(6-fluoro-2- naphthyl)methyl.phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide
The coupling reaction of the acid of Example 1 Step 5 with 5- bromo-2-methoxybenzesulfonamide (500 mg; 1.47 mmol) was done according to step 5 of example 1 to yield 662 mg (77%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR (DMSO-d6) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (IH, d),
7.17 (IH, d), 7.27 (IH, d), 7.35 (2H, m), 7.47 (IH, dd), 7.51 (IH, s), 7.58 (IH, d), 7.64 (IH, dd) and 7.75-7.90 (5H, ).
LRMS for M-l= 588.
EXAMPLE 15
(E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL)METHYL]PHENYL}-2-
PROPENOIC ACID SODIUM SALT (469)
Step 1: 6-Chloro-2-naphthol
The title compound was prepared from 2-(4- fluorophenyl)acetyl chloride according to step 3 of example 13.
Η NMR (CDClg) δ 7.10 (2H, m), 7.34 (IH, dd), 7.55-7.67 (2H, m) and 7.72 (IH, s).
Step 2: Ethyl (E)-3-(5-chloro-2-.(6-chloro-2-naphthyl)methyl1phenyl)-2- propenoate
The title compound was prepared according to step 4 of example 13 in 30% yield. Η NMR (CDClg) δ 1.23 (3H, t), 4.20 (4H, m), 6.29 (IH, d), 7.10
(IH, d), 7.22 (2H, m), 7.33 (IH, dd), 7.42 (IH, s), 7.53 (IH, d), 7.61 (2H, d), 7.70 (IH, s) and 7.91 (IH, d).
Step 3: (E)-3-(5-Chloro-2-r(6-chloro-2-naphthyl)methyllphenyl}-2- propenoic acid, sodium salt
The hydrolysis of the ester of Step 2 (620 mg; 1.6 mmol) was done according to step 4 of example 1 to yield 500mg (87%) of the title compound. Η NMR (CDClj) δ 4.22 (2H, s), 6.30 (IH, d), 7.15 (IH, d),
7.20-7.39 (3H, m), 7.43 (IH, s), 7.56 (IH, s), 7.62 (2H, t), 7.75 (IH, s) and
8.02 (IH, d).
Elemental analysis calcd for C20H13Cl2NaO2 .H20 : C, 60.48;
H, 3.78; Found C, 60.68, H, 3.63.
EXAMPLE 16
5-BROMO-N((E)-3-{5-CHLORO-2-[(6-CHLORO-2-NAPHTHYL-
2)METHYL]PHENYL}-2-PROPENOYL)-2- METHOXYBENZENESULFONAMIDE. SODIUM SALT (450)
Step 1: 5-Bromo -N-((E)-3-f5-chloro-2-_(6-chloro-2- naphthyl)methyl1phenyl}-2-propenoyl)-2-methoxybenzenesulfonamide The coupling reaction of the acid of Example 15 Step 3 (500 mg; 1.4 mmol) was done according to step 5 of example 1 with 5-bromo- 2-methoxybenzesulfonamide to yield 662 mg (74%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR (DMSO-d6) δ 3.78 (3H, s), 4.22 (2H, s), 6.53 (IH, d), 7.20 (IH, d), 7.30-7.40 (2H, m), 7.45 (2H, m), 7.55 (IH, s), 7.59 (IH, s), 7.79 (3H, m), 7.85-7.92 (2H, m) and 7.98 (IH, d).
Elemental analysis calcd for C27H19BrC12NNa04S .2H20 : C, 49.01; H, 3.33; N, 2.14; Found C, 48.89, H, 3.47; N, 2.11.
EXAMPLE 17 (E)-3-(5-CHLORO-2-{[6-DIFLUOROMETHOXY)-2- NAPHTHYLlMETHYLIPHENYL-2-PROPENOIC ACID. SODIUM SALT (505)
Step 1: 6-Bromo-2-difluoromethoxynaphthalene
Methyl chlorodifluoroacetate (5.3 mL) was added dropwise to 6-bromonaphthol (10.25 g; 45.9 mmol) and potassium carbonate (7.61g; 55.1 mmol) at 90 0C in 160 mL of DMF for 6 h. Purification by gel silica chromatography (3% EtOAc in hexane) gave 4.80 g (38%) of the title compound.
IH NMR (CDC13) δ 6.61 (IH, t), 7.31 (lH,dd), 7.48 (IH, d), 7.56 (IH, dd), 7.67 (IH, d), 7.72 (IH, d) and 8.01 (IH, d).
Step 2: Ethyl (E)-3-(5-chloro-2-..6-difluoromethoxy)-2- naphthyl.methyl}phenyl)-2-propenoate The corresponding boronic acid of the previous halide was coupled according to step 3 of example 1 of the title compound in 57% yield.
IH NMR (CDC13) δ 1.25 (3H, t), 4.22 (4H, m), 6.28 (IH, d), 6.53 (IH, t), 7.11 (IH, d), 7.25 (2H, m), 7.45 (2H, d), 7.55 (IH, d), 7.72 (2H, t) and 7.92 (IH, d).
Step 3: (E)-3-(5-Chloro-2-( [6-difluoromethoxy)-2-naphthyllmethyl)phenyl)- 2-propenoic acid, sodium salt
The hydrolysis of the ester of Step 2 (1.9 g; 4.7 mmol) was done according to step 4 of example 1 to yield 600mg of the title compound.
IH NMR of sodium salt (DMSO-d6) δ 4.20 (2H, s), 6.29 (IH, d), 7.10-7.40 (6H, ), 7.58 (3H, m) and 8.84 (2H, t).
HRMS calc'd for C2lHi4θ3F2ClNa +H= 411.0575; Found: 411.0577.
EXAMPLE 18 5-BROMO-N- [(E)-3-(5-CHLORO-2-{ [6-DIFLUOROMETHOXY)-2- NAPHTHYL_METHYL)-2-PROPENO YL] -2- METHOXYBENZENESULFONAMIDE. SODIUM SALT (447)
Step 1: 5-Bromo -N-.(E)-3-(5-chloro-2-U6-difluoromethoxy)-2- naphthyllmethyl)phenyl)-2-propenoyll-2-methoxybenzennesulfonamide
The coupling reaction of the acid of Example 17 Step 3 (l.OOg; 2.57 mmol) was done according to step 5 of example 1 with 5- bromo-2-methoxybenzesulfonamide to yield 915 mg (56%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR of sodium salt DMSO-d6) δ 3.66 (3H, s), 4.18 (2H, s), 6.36 (IH, d), 6.92 (IH, d), 7.20-7.35 (5H, m), 7.48 (2H, m), 7.55-7.65 (3H, m) and 7.80 (3H, m).
LRMS for M-l= 634. EXAMPLE 19
(E)-3- [2-(3,4-DICHLOROBENZYL)-5-CHLOROPHENYL] -2-PROPENOIC
ACID. SODIUM SALT (535)
Step 1: Ethyl (E)-3-.2-(3.4-dichlorobenzyl)-5-chlorophenyl)-2-propenoate The benzyl bromide of step 2 of example 13 was treated with
3,4-dichlorobenzeneboronic acid according to the procedure described in step 3 of example 1 to yield the title compound in 67% yield.
IH NMR (CDC13) δ 1.30 (3H, t), 4.00 (2H, s), 4.23 (2H, q), 6.30
(IH, d), 6.90 (lH,dd), 7.09 (IH, d), 7.15 (IH, s), 7.28 (IH, m), 7.32 (IH, d), 7.55 (IH, d) and 7.79 (IH, d).
Step 2: (E)-3-r2-(3.4-Dichlorobenzyl)-5-chlorophenyl)-2-propenoic acid. sodium salt
The hydrolysis of the ester of Step 1 (1.00 g; 2.7 mmol) was done according to step 4 of example 1 to yield 907 mg (98%) of the title compound.
IH NMR (CDC13) δ 3.95 (2H, s), 6.30 (IH, d), 6.86 (IH, d),
7.08 (2H, m), 7.32 (2H, m), 7.55 (IH, s) and 7.90 (IH, d).
LRMS for M-l= 339.
EXAMPLE 20 5-BROMO-N-{(E)-3-[5-CHLORO-2-(3,4-DICHLOROBENZYL)PHEI>ra__]-2- PROPENOYLI-2-METHOXYBEZENESULFONAMIDE. SODIUM SALT (421)
Step 1: 5-Bromo-N-{(E)-3-r5-chloro-2-)3.4-dichlorobenzyl)phenyll-2- propenoyll-2-methoxybenzenesulfonamide
The coupling reaction of the acid of Example 19 Step 2 (0.600 g; 1.75 mmol) was done according to step 5 of example 1 with 5-bromo-2- methoxybenzesulfonamide to yield 548 mg (53%) of the title compound. The sodium salt was prepared with IN NaOH. IH NMR (DMSO-d6) δ 3.85 (3H, s), 4.10 (2H, s), 6.54 (IH, s),
7.01 (IH, d), 7.22 (IH, d), 7.32 (2H, m), 7.40-7.50 (2H, m), 7.56 (IH, s), 7.67 (IH, d), 7.86 (IH, d), 7.91 (IH, s) and 12.37 (U, s). LRMS for M-l= 586.
EXAMPLE 21
5-BROMO-N-{(E)-3-[4-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL]-2- PROPENOYLl-2-METHOXYBENZENESULFONAMIDE. SODIUM SALT
(449)
Step 1: Ethyl (E)-3-f4-chloro-2-.(2-naphthylmethyl)phenyll-2-propenoate 2-Bromo-5-chloro toluene (20.0 g) was converted to the corresponding aldehyde and then to the cinnamate according to step 1 of example 13. This cinnamate was converted to the benzylic bromide according to step 2 of example 1 and coupled via a Suzuki coupling reaction according to step 3 of example 1 with naphthalene boronic acid to yield the title compound.
Η NMR (CDC13) δ 1.30 (3H, t), 4.22 (4H, m), 6.29 (IH, d), 7.15-7.27 (3H, m), 7.42 (2H, m), 7.52 (2H, m), 7.75 (3H, m) and 7.99 (IH, d).
Step 2: (E)-3-.4-Chloro-2-[(2-naphthylmethyl)phenyl}-2-propenoic acid (530)
The hydrolysis of the ester of Step 1 (0.56 g; 1.57 mmol) was done according to step 4 of example 1 to yield 450 mg (88%) of the title compound. Η NMR (CDClg) δ 4.24 (2H, s), 6.30 (IH, d), 7.20-7.30 (3H, m), 7.42 (2H, m), 7.51 (2H, m), 7.75 (3H, m) and 8.09 (IH, d). LRMS for M-l= 321.
Step 3: 5-Bromo-N-f . (E)-3- .4-chloro-2-(2- naphthylmethyl)phenyllpropenoyl)-2-methoxybenzenesulfonamide The coupling reaction of the acid of Step 2 (0.296 g; 0.89 mmol) was done according to step 5 of example 1 with 5-bromo-2- methoxybenzesulfonamide to yield 213 mg (42%) of the title compound. The sodium salt was prepared with IN NaOH. Η NMR (ACETONE-MEOH-d6) δ 3.70 (3H, s), 4.20 (2H, s), 6.44 (IH, d), 6.95 (2H, m), 7.25 (3H, m), 7.40 (2H, m), 7.55 (3H, m), 7.75 (3H, m), 7.95 (IH, d) and 8.02 (IH, d).
LRMS for M-l= 568.
EXAMPLE 22
(E)-3-[5-METHOXY-2-(2-NAPHTHMETHYL)PHENYL]-2-PROPENOIC
ACID. SODIUM SALT (534)
Step 1: (2-Bromo-4-methoxyphenyl)(2-naphthyl)methanone AICI3 (17.48 g; 131.1 mmol) was added portionwise to a mixture of 3-bromocresol (16.04 g; 87.4 mmol) and 2-naphthoyl chloride (25.00 g; 131.1 mmol) in 50 mL of CHC13 gave 14.0 g (47%) of the title compound.
IH NMR (CDC13) δ 3.78 (3H, s), 6.92 (IH, dd), 7.19 (IH, d), 7.38 (IH, d), 7.50 (IH, t), 7.59 (IH, t), 7.89 (3H, m), 7.95 (IH, dd) and 8.18 (IH, s).
Step 2: 2-(2-Bromo-4-methoxybenzyl)naphtalene
To the methanone of Step 1 (14.0 g) and triethylsilane (15 mL) in 15 mL of CHCI3 was added TFA and was heated to 50°C overnight. The solution was cooled and quenched with NaOH (2N) to provide the title compound in 82% yield.
IH NMR (CDC13) δ 3.75 (3H, s), 4.20 (2H, s), 6.75 (IH, dd), 7.07 (IH, d), 7.12 (IH, s), 7.30 (IH, d), 7.42 (2H, m), 7.58 (IH, s) and 7.76 (3H, m).
Step 3: Ethyl (E)-3-[5-methoxy-2-(2-naphthylmethyl)phenyll-2- propenoate
The naphthalene of Step 2 was converted to the corresponding aldehyde according to the step 1 of example 13 in 98% yield. This aldehyde was then converted to the cinnamate according to step 1 of example 13 in 90% yield.
IH NMR (CDC13) δ 3.70 (3H, s), 4.11 (4H, m), 6.20 (IH, d), 6.77 (IH, dd), 6.99 (IH, d), 7.03 (IH, d), 7.15 (IH, d), 7.30 (2H, m), 7.39 (IH, s), 7.60-7.70 (3H, m) and 7.90 (IH, s).
Step 4: (E)-3-.5-Methoxy-2-(2-naphthmethyl)phenyl.-2-propenoic acid The hydrolysis of the ester of Step 3 (2.83 g; 8.2 mmol) was done according to step 4 of example 1 to yield 2.16 g (83%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR (CDC13) δ 3.70 (3H, s), 4.13 (2H, s), 6.20 (IH, d), 6.80 (IH, dd), 7.02 (2H, m), 7.15 (IH, d), 7.29 (2H, m), 7.39 (IH, s), 7.62 (3H, m) and 8.03 (IH, d).
LRMS calcd for M-l= 317.
EXAMPLE 23
5-BROMO-2-METHOXY-N-{(E)-3-[5-METHOXY-2-(2-
NAPHTHYLMETHYDPHENYL] -2-
PROPENOYLIBENZENESULFONAMIDE SODIUM SALT (448)
Step 1: 5-Bromo-2-methoxy-N-!(E)-3-r5-methoxy-2-(2- naphthylmethyl)phenyll-2-propenoyl}benzenesulfonamide
The coupling reaction of the acid of Example 22 Step 4 (0.600 g; 1.88 mmol) was done according to step 5 of example 1 with 5-bromo-2- methoxybenzesulfonamide to yield 573 mg (57%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR (CDC13) δ 3.72 (3H, s), 3.77 (3H, s), 4.13 (2H, s), 6.40 (IH, d), 6.70 (IH, d), 6.85 (IH, dd), 7.02 (IH, d), 7.10-7.20 (2H, m), 7.37 (3H, m), 7.57 (IH, dd), 7.60-7.80 (3H, m),7.95 (IH, d), 8.15 (IH, d) and 9.12 (IH, broad s). LRMS calcd for M-l= 564.
EXAMPLE 24 (E)-3- [5-CHLORO-2-(4-CHLOROBENZYL)PHENYL] -2-PROPENOIC ACID SODIUM SALT (537)
Step 1: Ethyl(E)-3-r5-chloro-2-(4-chlorobenzyl)phenvn-2-propenoate The benzyl bromide of step 2 of example 13 was coupled in a
Suzuki coupling reaction with 4-chlorobenzene boronic acid according to the procedure of step 2 example 1 to yield 69% of the title compound.
IH NMR (CDC13) δ 1.30 (3H, t), 4.02 (2H, s), 4.22 (2H, q), 6.29 (IH, d), 6.99 (2H, d), 7.08 (IH, d), 7.20-7.30 (3H, m), 7.52 (IH, s) and 7.83 (IH, d).
Step 2: (E)-3-f5-Chloro-2-(4-chlorobenzyl)phenyH-2-propenoic acid
The hydrolysis of the ester of Step 1 (1.14 g; 3.4 mmol) was done according to step 4 of example 1 to yield 860 mg (83%) of the title compound. The sodium salt was prepared with IN NaOH.
IH NMR (CDC13) δ 4.04 (2H, s), 6.30 (IH, d), 7.00 (2H, d),
7.10 (IH, d), 7.23 (2H, d), 7.29 (IH, d), 7.55 (IH, s) and 7.95 (IH, d). LRMS calcd for M-l= 305.
EXAMPLE 25
(E)-3-{2-[(5-(PHENYLMETHOXY)INDOLYL)METHYL]-5-
FLUOROPHENYL}-N-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-
2-PROPENAMIDE (451)
Step 1: Ethyl (E)-3-(5-fluoro-2-methylphenyl)-2-propenoate
5-Fluoro-2-methylbenzaldehyde (40.58 g; 294 mmol) was converted to the ethyl cinnamate according to step 1 of example 1 to yield 40.81 g. of the title compound. Η NMR (acetone-d6) δ 1.29 (3H, t), 2.40 (3H, s), 4.23 (2H, q),
6.49 (IH, d), 7.07 (IH, td), 7.29 (IH, dd), 7.46 (IH, dd) and 7.87 (IH, dd).
Step 2: Ethyl (E)-3-f2-(bromomethyl)-5-fluorophenyl.-2-propenoate
The ester of Step 1(40.80 g; 196 mmol) was converted to the benzylic bromide according to step 2 of example 1 to yield 24.17 g of the title compound.
Η NMR (acetone-d6) δ 1.30 (3H, t), 4.24 (2H, q), 4.81 (2H, s), 6.62 (IH, d), 7.18 (IH, td), 7.58 (2H, m) and 8.02 (IH, dd). Step 3: Ethyl (E)-3-{2-[(5-(phenylmethoxy)indolyl)methyl]-5- fluorophenyl)-2-propenoate
The benzylic bromide of Step 2 (3.16 g; 11.0 mmol) was coupled with 5-(phenylmethoxy)indole according to the same procedure described in step 1 of example 2 to yield 2.27 g of the title compound. Η NMR (acetone-d6) δ 1.27 (3H, t), 4.20 (2H, q), 5.11 (2H, s),
5.59 (2H, s), 6.43 (IH, dd), 6.52 (IH, d), 6.80 (IH, dd), 6.86 (IH, dd), 7.08 (IH, td), 7.19 (IH, d), 7.22 (IH, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.55 (IH, dd) and 8.01 (IH, dd).
Step 4: (E)-3-{2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl}-2- propenoic acid (493)
The hydrolysis of the ester of Step 3 (2.27 g) was done according to step 4 of example 1 to yield 2.07 g of the title compound.
Η NMR (acetone-d6) δ 5.11 (2H, s), 5.62 (2H, s), 6.43 (IH, dd), 6.53 (IH, d), 6.75 (IH, dd), 6.86 (IH, dd), 7.08 (IH, td), ), 7.19 (IH, d), 7.25 (IH, d), 7.31 (2H, m), 7.38 (2H, m), 7.50 (2H, m), 7.56 (IH, dd) and 8.04 (IH, dd). Elemental analysis calcd. for C25H20FNO3.2H2O: C, 68.64; H, 5.53; N, 3.20; Found: C, 68.16; H, 4.95; N, 3.06.
Step 5: (E)-3-{2-[(5-(Phenylmethoxy)indolyl)methyl]-5-fluorophenyl}-N- ■(5-bromo-2-methoxyphenyl)sulfonyll-2-propenamide
The acid of Step 5 (2.06; 5.13 mmol) was coupled with 5- bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 2.44 g of the title compound. Η NMR (acetone-d6) δ 3.93 (3H, s), 5.10 (2H, s), 5.59 (2H, s),
6.39 (IH, dd), 6.73 (IH, dd), 6.78 (IH, d), 6.81 (IH, dd), 7.09 (IH, td), ), 7.18 (IH, d), 7.24 (3H, m), 7.32 (IH, m), 7.39 (3H, m), 7.49 (2H, m), 7.82 (IH, dd), 8.01 (IH, dd) and 8.09 (IH, d). Elemental analysis calcd. for C32H26BrFN205S2: C, 59.17; H, 4.03; N, 4.31; S, 4.94; Found: C, 59.07; H, 4.01; N, 4.34; S, 5.16.
EXAMPLE 26 (E)-3- [2-(BENZO [B]THIOPHEN-2-YLMETHYL)-5-FLUOROPHENYL] -N- [(5-BROMO-2-METHOXYPHENYL)SULFONYL]-2-PROPENAMIDE
SODIUM SALT (452)
Step 1: Ethyl (E)-3-.2-(benzo.b1thiophen-2-ylmethyl)-5-fluorophenvH-2- propenoate
The ester (901 mg, 3.14 mmol) of example 13, step 2 was coupled with benzo[b]thiophene-2-boronic acid (from Lancaster
Chemical) in DME according to the same procedure described in step 3 of example 10 to yield 657 mg of the title compound. Η NMR (acetone-d6) δ 1.22 (3H, t), 4.16 (2H, q), 4.43 (2H, s),
6.50 (IH, d), 7.03 (IH, s), 7.15-7.35 (3H, m), 7.47 (IH, dd), 7.56 (IH, dd),
7.69 (IH, dd), 7.78 (IH, dd) and 8.00 (IH, dd).
Step 2: (E)-3- 2-(benzorblthiophen-2-ylmethyl)-5-fluorophenyll-2- propenoic acid (539)
The hydrolysis of the ester of Step 1 (657 mg) was done according to step 4 of example 1 to yield 345 mg of the title compound.
Η NMR (acetone-d6) δ 4.45 (2H, s), 6.51 (IH, d), 7.04 (IH, d), 7.2-7.3 (3H, m), 7.49 (IH, dd), 7.57 (IH, dd), 7.70 (IH, d), 7.80 (IH, m) and 8.01 (IH, dd). Elemental analysis calcd. for C18H13F02S: C, 69.21; H, 4.19; Found: C, 68.96; H, 4.15.
Step 3: (E)-3-[2-(Benzo[b]thiophen-2-ylmethyl)-5-fluorophenyl]-N-[(5- bromo-2-methoxyphenyl)sulfonyl1-2-propenamide The previous acid (264 mg; 0.85 mmol) was coupled with 5- bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 287 mg of the title compound.
Η NMR (acetone-d6) δ 3.83 (3H, s), 4.43 (2H, s), 6.77 (IH, d), 7.00 (IH, d), 7.13 (IH, d), 7.2-7.3 (3H, m), 7.41 (IH, dd), 7.49 (IH, dd), 7.65 (IH, dd), 7.78 (2H, m), 7.96 (IH, dd)HH and 8.05 (IH, d).
The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C25H18BrFNNa04S2.H20: C, 50.01; H, 3.36; N, 2.33; Found: C, 49.84; H, 3.22; N, 2.41. EXAMPLE 27
N-(E)-[(5-BROMO-2-METHOXYPHENYL)SULFONYL]-3-(5-FLUORO-2- {[l-BENZYLINDOL-5-YL]METHYL}PHENYL)-2-PROPENAMIDE
SODIUM SALT (453)
Step 1: Ethyl (E)-3-[5-fluoro-2-(indol-5-ylmethyl)phenyll-2-propenoate The ester (1.83 g, 6.37 mmol) of example 13, step 2 was coupled with 5-indolyl boronic acid and NaHC03 in DME according to the procedure described in step 3 of example 10 to yield 1.08 g of the title compound. Η NMR (acetone-d6) δ 1.26 (3H, t), 4.17 (2H, q), 4.21 (2H, s),
6.37 (IH, m), 6.44 (IH, d), 6.94 (IH, dd), 7.14 (IH, td), 7.27-7.37 (4H, m),
7.51 (IH, dd), 8.05 (IH, dd) and 10.13 (IH, s).
Step 2: Ethyl (E)-3-(5-fluoro-2-( ■ l-benzylindol-5-yl1methyl}phenyl)-2- propenoate
The indole of Step 1 (621 mg; 1.92 mmol) was coupled with benzyl bromide according to the procedure described in step 1 of example 2 to yield 678 mg of the title compound.
Η NMR (acetone-d6) δ 1.26 (3H, t), 4.17 (4H, m), 5.32 (2H, s), 6.43 (2H, m), 6.95 (IH, dd), 7.1-7.4 (11H, m), 7.49 (IH, dd) and 8.08 (IH, dd).
Step 3: (E)-3-(5-Fluoro-2-( [l-benzylindol-5-ynmethyllphenyl)-2-propenoic acid) (540) The hydrolysis of the ester of Step 2 (678 mg) was done according to step 4 of example 1 to yield 276 mg of the title compound.
Η NMR (acetone-d6) δ 4.20 (2H, s), 5.38 (2H, s), 6.39 (IH, d),
6.45 (IH, d), 6.95 (IH, d), 7.1-7.3 (10H, m), 7.48 (IH, d) and 8.04 (IH, dd).
Elemental analysis calcd. for C25H20FNO2: C, 77.91; H, 5.23; N, 3.63; Found: C, 78.52; H, 5.46; N, 3.66.
Step 4: N-(E)-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-(5-fluoro-2-{[l- benzylindol-5-yllmethyl}phenyl)-2-propenamide The acid of Step 3 (219 mg; 0.57 mmol) was coupled with 5- bromo-2-methoxybenzenesulfonamide of example 10, step 5 according to step 5 of example 1 to yield 149 mg of the title compound.
Η NMR (acetone-d6) δ 3.82 (3H, s), 4.18 (2H, s), 5.38 (2H, s), 6.36 (IH, dd), 6.72 (IH, d), 6.90 (IH, dd), 7.1-7.4 (12H, m), 7.78 (IH, dd), 7.98 (IH, dd) and 8.05 (IH, d).
The acid was converted to the sodium salt with 1 equivalent of NaOH. Elemental analysis calcd. for C32H25BrFN2Na04S.l/2H20: C, 57.84; H, 3.94; N, 4.22; Found: C, 57.61; H, 3.86; N, 4.16.
EXAMPLE 28
N-(E)-[(2,4-DIMETHYL(l,3-THIAZOL-5-YL))SULFONYL]-3-{3-[(5- CHLOROINDOLYDMETHYLl (2-PYRIDYD1-2-PROPENAMIDE (444)
Step 1: Ethyl (E)-3-(3-methyl-2-pyridyl)-2-propenoate To a solution of 2-bromo-3-methylpyridine (10.36 g; 60.2 mmol) in 120 mL of THF at -100 °C was added dropwise a 1.6 M solution of n-BuLi (65.6 mmol). After 20 min of stirring at that temperature, 1- formylpiperidine (7.65 g) in 10 mL of THF was added and the solution was warmed to r.t.. After 30 min of stirring at r.t., triethyl phosphonoacetate (13.7 mL; 69.1 mmol) was added dropwise below 30 °C . After 1 h of stirring, the mixture was quenched with NH4OAc (25%) and extracted with EtOAc. The solvent was removed and the crude oil was purified by silica gel chromatography (25% EtOAc in hexane) to yield 10.32 g of the title compound. Η NMR (acetone-d6) δ 1.29 (3H, t), 2.46 (3H, s), 4.22 (2H, q),
6.99 (IH, d), 7.27 (IH, dd), 7.64 (IH, dt), 7.90 (IH, d) and 8.45 (IH, m).
Step 2: Ethyl (E)-3-.3-(bromomethyl)-2-pyridyl1-2-propenoate
The ester of Step 1 (5.93 g; 31.0 mmol) was converted in benzene to the benzylic bromide according to the procedure described in step 2 of example 1 to yield 1.83 g of the title compound.
Η NMR (acetone-d6) δ 1.30 (3H, t), 4.25 (2H, q), 4.88 (2H, s), 7.10 (IH, d), 7.41 (IH, dd), 7.91 (IH, dd), 8.03 (IH, d) and 8.60 (IH, dd).
Step 3: Ethyl (E)-3-.3-.(5-chloroindolyl)methyl1-2-pyridyll-2-propenoate The benzylic bromide of Step 2 (1.33 g; 4.91 mmol) was coupled with 5-chloroindole according to the procedure described in step 1 of example 2 to yield 1.22 g of the title compound.
Η NMR (acetone-d6) δ 1.28 (3H, t), 4.22 (2H, q), 5.78 (2H, s), 6.57 (IH, d), 6.94 (IH, d), 7.04 (IH, d), 7.11 (IH, dd), 7.27 (IH, dd), 7.43 (2H, m), 7.63 (IH, d), 7.99 (IH, d) and 8.53 (IH, d).
Step 4: (E)-3-.3-.(5-Chloroindolyl)methyll-2-pyridyl}-2-propenoic acid
(542) The hydrolysis of the ester of Step 3 (283 mg) was done according to step 4 of example 1 to yield 291 mg of the title compound.
Η NMR (acetone-d6) δ 5.81 (2H, s), 6.57 (IH, d), 6.88 (IH, d), 7.05 (IH, d), 7.11 (IH, dd), 7.26 (IH, dd), 7.43 (2H, m), 7.63 (IH, d), 8.02 (IH, d) and 8.54 (IH, d). Elemental analysis calcd. for C17H13C1N202.1/4H20: C, 64.36; H, 4.29; N, 8.83; Found: C, 64.63; H, 4.43; N, 8.65.
Step 5: N-(E)-r(2.4-Dimethyl(1.3-thiazol-5-yl))sulfonyl.-3-f3-.(5- chloroindolyl)methyll(2-pyridyl))-2-propenamide The acid of Step 4 (283 mg; 0.90 mmol) was coupled with 2,4- dimethyl-l,3-thiazole-5-sulfonamide (from Maybridge Chemical) according to step 5 of example 1 to yield 315 mg of the title compound.
Η NMR (acetone-d6) δ 2.64 (3H, s), 2.69 (3H, s), 5.81 (2H, s),
6.56 (IH, d), 6.84 (IH, d), 7.09 (IH, dd), 7.26 (IH, dd), 7.31 (IH, d), 7.41 (2H, m), 7.62 (IH, d), 8.05 (IH, d) and 8.51 (IH, d). Elemental analysis calcd. for C22H19C1N403S2: C, 54.26; H, 3.93; N, 11.50; S, 13.17; Found: C, 54.69;
H, 4.03; N, 11.18; S, 12.89.
EXAMPLE 29 N-{(E)-3- [5-CHLORO-2-(2-NAPHTHYLMETHYL)PHENYL] -2-
PROPENOYL-2-METHOXYBENZENESULFONAMIDE (302)
The coupling reaction of the acid (3.00 g; 9.1 mmol) of Step 5 in Example 12 was done with 5-bromo-2-methoxybenzesulfonamide (2.56g; 9.6 mmol) according to Step 5 of Example 1 to yield 4.13g (79 %) of the title compound. The sodium salt was prepared with IN NaOH.
Η NMR (DMSO-d6) d 3.76 (3H, s), 4.25 (2H, s), 6.52 (IH, d), 7.15 (IH, d), 7.26 (IH, d), 7.36 (IH, d), 7.41-7.52 (4H, ), 7.58 (IH, s), 7.69 (IH, m), 7.78 (IH, d), 7.82 (3H, m), 7.89 (IH, d) and 12.38 (IH, br s).
Elemental analysis:
Calcd. for C27H2θBrClNNaθ4S.H2θ: C, 53.08; H, 3.64; N, 2.29;
Found: C, 53.25; H, 3.89; N, 2.91. These intermediates were prepared according to the literature: 5-fiuoro-2-methylbenzaldehyde:
Servis, K. L.; Fang, K.-N. J. Am. Chem. Soc. 1968, 90, 6712- 6717. 5-indolyl boronic acid:
Yang, Y.; Martin, A. R. Heterocycles 1992, 34, 1395-1398.

Claims

WHAT IS CLAIMED IS:
A compound represented by formula I:
Figure imgf000111_0001
I or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein: HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(0)n and N(0)m wherein m is 0 or 1 and n is 0, 1 or 2;
A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)- , -C(R7)2-W- , -W-C(R7)2 - , -CR7(OR20)- ,
-C(R7)2 - , -C(R7)2-C(OR20)R7 - , -C(R7)2- C(R7)2- or -CR7=CR7- , wherein W represents O, S(0)n or NR17, with n as previously defined and Rl7 as defined below;
X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0)m , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other; Y represents O, S(0)n , NR17, a bond or -CR18 = CR18- ; B represents - (C(Rl8)2)p-Y- (C(Rl8)2)q - wherein p and q are independently 0-3, such that when Y represents O, S(0)n , NR17 or -CR18 = CR18- , p + q = 0-6, and when Y represents a bond, p + q is 1-6;
Z is OH or NHS02R 19 R1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(Ra)4_9 , -
(C(R )2)PSR5, -(C(R4)2)pOR8, -(C(R4)2)pN(R6)2, CN, N02, -(C(R4)2)pC(R7)3, C02R9, -CON(R6)2 or -(C(R )2)pS(0)nR10, wherein n and p are as previously defined; each R4 is independently H, F, CF3 or lower alkyl, or two R4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from 0, S(0)n or N(0)m; each R5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET, lower alkenyl-HET or -(C(R18)2 )pPh(Ru)θ- 2; each R6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn and when two R6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0)n or N(0)m; each R7 is independently H, F, CF3 or lower alkyl, and when two R7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(0)n and N(0)m; each R8 represents H or R5; each R9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn; each R10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(Rn)θ-3. CH2Ph(Rn)θ-3 or N(R6)2 ; each R11 is independently lower alkyl, SR20, OR20, N(R6)2,
-C02R12, -CON(R6)2, -C(0)R12, CN, CF3, N02 or halogen; each R12 is independently H, lower alkyl or benzyl; each R13 is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R6)2, C02R12, CN, CF3 or NO; 2 > R14 and Rl5 are independently lower alkyl, halogen, CF3,
OR16, S(0)nR16 or C(R16)2OR17 ; each R16 is independently H, lower alkyl, lower alkenyl, Ph, Bn or CF3. each R17 is independently H, lower alkyl or Bn; each R18 is independently H, F or lower alkyl, and when two
R18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0)n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF3 ,
HET(Ra)4_9, lower alkyl-HET(Ra)4_9 or lower alkenyl-HET(Ra)4_9; each R20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3 or Ph(R13)2 and each Ra is independently selected from the group consisting of:
H, OH, halo, CN, Nθ2, amino, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Ci-βalkylamino, di-Ci- βalkylamino, CF3, C(0)Cι_6alk l, C(0)C2-6alkenyl, C(O) C2-6alkynyl, CO2H, C02Cι_6alkyl,
Cθ2C2-6alkenyl, and Cθ2C2-6alkynyl, said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, Ci-β alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(0)C2-6alkynyl, CO2H, Cθ2Ci-6alkyl, Cθ2C2-6alkenyl, Cθ2C2-6alkynyl, NH2, NHCl- 6alkyl and N(Ci-6alkyl)2.
A compound represented by formula I:
Figure imgf000113_0001
I or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein:
HET represents a 5-12 membered monocyclic or bicyclic aromatic ring system containing 0-3 heteroatoms selected from O, S(0)n and N(0) wherein m is 0 or 1 and n is 0, 1 or 2;
A is a one or two atom moiety and is selected from the group consisting of: -W-, -C(O)- , -C(R7)2-W- , -W-C(R7)2 - , -CR7(OR20)- , -C(R7)2 - , -C(R7)2-C(OR20)R7 - , -C(R7)2- C(R7)2- or -CR7=CR7- , wherein W represents O, S(0)n or NR17, with n as previously defined and Rl? as defined below; X represents a 5-10 membered monocyclic or bicyclic aryl or heteroaryl group having 1-3 heteroatoms selected from O, S(0)n and N(0) , and optionally substituted with Rl4 and Rl5, and A and B are attached to the aryl or heteroaryl group ortho relative to each other; Y represents O, S(0)n , NR17, a bond or -CR18 = CR18- ; B represents - (C(Rl8)2)p-Y- (C(Rl8)2)q - wherein p and q are independently 0-3, such that when Y represents O, S(0)n , NR17 or -CR18 = CR18- , p + q = 0-6, and when Y represents a bond, p + q is 1-6;
Z is OH or NHS02R19 ; R1 R2 and R3 independently represent H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET(Ra)4_9 .
-(C(R4)2)pSR5, -(C(R4)2)pOR8, -(C(R4)2)pN(R6)2, CN, N02, -(C(R4)2)pC(R7)3, -C02R9, -CON(R6)2 or -(C(R )2)pS(0)nR10, wherein n and p are as previously defined; each R4 is independently H, F, CF3 or lower alkyl, or two R4 groups are taken in conjunction and represent a ring of up to six atoms, optionally containing one heteroatom selected from O, S(0)n or N(0)m; each R5 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET, lower alkenyl-HET or -(C(R18)2 )pPh(Rn)θ-
2; each R6 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn and when two R6 groups are attached to N they may be taken in conjunction and represents a ring of up to 6 atoms, optionally containing an additional heteroatom selected from O, S(0)n or
N(0)m; each R7 is independently H, F, CF3 or lower alkyl, and when two R7 groups are presents, they may be taken in conjunction and represent an aromatic or aliphatic ring of 3 to 6 members containing from 0-2 heteroatoms selected from O, S(0)n and N(0)m; each R8 represents H or R5; each R9 is independently H, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn; each R10 is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(Rn)0-3. CH2Ph(Rn)0-3 or N(R6)2 ; each R11 is independently lower alkyl, SR20, OR20, N(R6)2, -C02R12, -CON(R6)2, -C(0)R12, CN, CF3, N02 or halogen; each R12 is independently H, lower alkyl or benzyl; each R13 is independently H, halo, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R6)2, C02R12, CN, CF3 or N0 '22 »
R14 and Rl5 are independently lower alkyl, halogen, CF 33' OR16, S(0)nR16 or C(R16)2OR17 ; each R16 is independently H, lower alkyl, lower alkenyl, Ph, Bn, CHF2 or CF3. each R17 is independently H, lower alkyl or Bn; each R18 is independently H, F or lower alkyl, and when two R18 groups are present, they may be taken in conjunction and represent a ring of 3 to 6 members comprising carbon atoms and optionally one heteroatom chosen from O, S(0)n or N; each R is lower alkyl, lower alkenyl, lower alkynyl, CF 3 '
HET2(Ra)4_9> lower alkyl-HET2(Ra)4_9 0r lower alkenyl-HET2(Ra)4_9) wherein HET2 represents a member selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl; each R20 is independently H, lower alkyl, lower alkenyl, lower alkynyl, CHF2 , CF3 or Ph(R13)2 and each Ra is independently selected from the group consisting of: H, OH, halo, CN, NO2, amino, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, Cι_6alkylamino, di-Ci- βalkylamino, CF3, C(0)Ci-6alkyl, C(0)C2-6alkenyl, C(O) C2-6alkynyl, CO2H, Cθ2Ci-6alkyl, CC Ctø-βalkenyl, and Cθ2C2-6alkynyl, said alkyl, alkenyl, alkynyl and the alkyl portions of alkylamino and dialkylamino being optionally substituted with 1-3 of: hydroxy, halo, aryl, Ci-6 alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, CF3, C(0)Ci_6alkyl, C(0)C2-6alkenyl, C(0)C2-6alkynyl, CO2H, Cθ2Cι_6alkyl, Cθ2C2-6alkenyl, Cθ2C2-6alkynyl, NH2, NHCi-βalkyl and N(Ci-6alkyl)2.
3. A compound in accordance with claim 1 wherein: HET represents a member selected from the group consisting of: benzene, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, triazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole, 1,3- methylenedioxobenzene and pyrrole.
4. A compound in accordance with claim 3 wherein: HET is selected from the group consisting of: phenyl, biphenyl, naphthyl, indole, thiophene, benzofuran and quinoline.
5. A compound in accordance with claim 1 wherein:
A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), Sθ2, CH2, -C(O)- , -OCH2-, -CHOH- , -C(OH)(CH3)- and -CH2-O- .
6. A compound in accordance with claim 5 wherein: A is selected from the group consisting of: : S, S(O), SO2, CH2 and -C(O)-.
7. A compound in accordance with claim 1 wherein:
X represents phenyl optionally substituted with R14 and R15.
8. A compound in accordance with claim 7 wherein X represents phenyl and R14 and R15 are absent or represent halo.
9. A compound in accordance with claim 1 wherein: B represents CH=CH or 1,2-cyclopropyl.
10. A compound in accordance with claim 9 wherein: B represents CH=CH in the E-isomeric form.
11. A compound in accordance with claim 9 wherein:
Z is NHS02R19 .
12. A compound in accordance with claim 11 wherein: Z is NHS02R19 and R19 represents a member selected from the group consisting of: lower alkyl and HET(Ra)3.
13. A compound in accordance with claim 12 wherein: R19 represents HET(Ra)3 and HET is selected from the group consisting of: phenyl, thienyl, naphthyl, furanyl, thiazolyl, imidazolyl and indolyl.
14. A compound in accordance with claim 12 wherein: Z is NHS02R19 and R19 represents benzene or thiophene, substituted with (Ra)3.
15. A compound in accordance with claim 1 wherein: Z represents OH.
16. A compound in accordance with claim 1 wherein: HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole; A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), Sθ2, CH2, -C(O)- , -OCH2- , -CHOH- , - C(OH)(CH3 )- and -CH2-O-;
X represents phenyl optionally substituted with R14 and R15 ; B is CH=CH; Z is NHS02R19 and
R19 represents a member selected from the group consisting of: lower alkyl and HET(Ra)3.
17. A compound in accordance with claim 1 wherein:
HET represents a member selected from the group consisting of: phenyl, naphthalene, biphenyl, pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, oxazole, thiazole, imidazole, benzothiazole, 1,2,5-thiadiazole, thienopyridine, indole, tetrazole, imidazole, benzoxazole and pyrrole;
A represents a one or two atom moiety and is selected from the group consisting of: S, S(O), SO2, CH2, -C(O)- , -OCH2- , -CHOH- , -C(OH)(CH3 )- and -CH2-O-;
X represents phenyl optionally substituted with R14 and R15 ; B is CH=CH;
Z is OH.
18. A compound represented in one of the following tables:
Table I
Figure imgf000118_0001
la
(Compounds 1-323 and 347-454)
Figure imgf000118_0002
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000137_0002
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
wherein D= -0(CH2)3-0, Qn= 7-chloroquinolin-2-yl, 1,2-Ph = 1,2-benzenediyl, Rs = -CH2SCH2CH2Ph, Pyr = pyridinediyl, c-pr = cyclopropyl and Bn = benzyl.
19. A pharmaceutical composition which is comprised of a compound in accordance with any one of claims 1 to 18 in combination with a pharmaceutically acceptable carrier.
20. A method of treating or preventing a prostaglandin mediated disease which is comprised of administering to a mammalian patient in need of such treatment a compound in accordance with claim 1 in an amount which is effective for treating or preventing a prostaglandin mediated disease.
21. A method in accordance with claim 19 wherein the prostaglandin mediated disease is selected from the group consisting of: pain, fever or inflammation associated with rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures, immune and autoimmune diseases; cellular neoplastic transformations or metastic tumor growth; diabetic retinopathy, tumor angiogenesis; δ prostanoid-induced smooth muscle contraction associated with dysmenorrhea, premature labor, asthma or eosinophil related disorders;
Alzheimer's disease; glaucoma; 10 bone loss; osteoporosis; promotion of bone formation; Paget's disease; cytoprotection in peptic ulcers, gastritis, regional enteritis, lδ ulcerative colitis, diverticulitis or other gastrointestinal lesions; GI bleeding and patients undergoing chemotherapy; coagulation disorders selected from hypoprothrombinemia, haemophilia and other bleeding problems; kidney disease; 20 thrombosis; occlusive vascular disease; presurgery; and anti-coagulation.
2δ 22. A method in accordance with claim 20 wherein the prostaglandin mediated disease is selected from the group consisting of: pain, fever or inflammation.
23. A method in accordance with claim 20 wherein the 30 prostaglandin mediated disease is dysmenorrhea.
24. A method in accordance with claim 20, wherein the compound is co-administered with other agents or ingredients.
3δ 2δ. A method in accordance with claim 24 wherein the compound I is co-administered with another agent or ingredient selected from the group consisting of: an analgesic selected from acetaminophen, phenacetin, aspirin, a narcotic; a COX-2 selective NSAID and a conventional NSAID; caffeine; an H2-antagonist; aluminum or magnesium hydroxide; simethicone; a decongestant selected from phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive selected from codeine, hydrocodone, caramiphen, carbetapentane and dextramethorphan; another prostaglandin ligand selected from misoprostol, enprostil, rioprostil, ornoprostol and rosaprostol; a diuretic; and a sedating or non-sedating antihistamine.
26. Use of a compound, salt, hydrate or ester as defined in any one of claims 1 to 18 in the manufacture of a medicament for treatment or prevention of a prostaglandin mediated disease.
27. A compound, salt, hydrate or ester as defined in any one of claims 1 to 18 for use in the treatment or prevention of a prostaglandin mediated disease.
28. A prostaglandin antagonist pharmaceutical composition comprising an acceptable prostaglandin antagonistic amount of a compound, salt, hydrate or ester as defined in any one of claims 1 to 18, in association with a pharmaceutically acceptable carrier.
PCT/CA1999/000212 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment WO1999047497A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002322742A CA2322742A1 (en) 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
JP2000536694A JP2002506851A (en) 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU27086/99A AU756333B2 (en) 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EP99907214A EP1071648A2 (en) 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7799098P 1998-03-13 1998-03-13
US60/077,990 1998-03-13
GB9815856.1 1998-07-21
GBGB9815856.1A GB9815856D0 (en) 1998-07-21 1998-07-21 Carboxylic acids and acylsulfonamides compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
WO1999047497A2 true WO1999047497A2 (en) 1999-09-23
WO1999047497A3 WO1999047497A3 (en) 1999-10-28

Family

ID=26314084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000212 WO1999047497A2 (en) 1998-03-13 1999-03-12 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment

Country Status (2)

Country Link
EP (1) EP1071648A2 (en)
WO (1) WO1999047497A2 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081312A2 (en) * 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
WO2002002522A1 (en) * 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
WO2002018333A1 (en) * 2000-08-31 2002-03-07 Pfizer Limited Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
WO2002032900A2 (en) * 2000-10-19 2002-04-25 Pfizer Pharmaceuticals Inc. Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
WO2003024484A1 (en) * 2001-09-14 2003-03-27 Ono Pharmaceutical Co., Ltd. Remedies for pruritus
WO2003043655A1 (en) * 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US6956050B2 (en) 2002-04-12 2005-10-18 Pfizer, Inc. Imidazole compounds as anti-inflammatory and analgesic agents
WO2007018314A2 (en) * 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007027630A2 (en) * 2005-08-30 2007-03-08 Smithkline Beecham Corporation Genes associated with type ii diabetes mellitus
US7279477B2 (en) 2001-01-26 2007-10-09 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7285562B2 (en) 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
US7335776B2 (en) 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient
US7385063B2 (en) 2001-01-26 2008-06-10 Chugai Seiyaku Kabushiki Kaisha Method for preparing imidazole derivatives
WO2008099907A1 (en) 2007-02-16 2008-08-21 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
US7449482B2 (en) 2003-08-01 2008-11-11 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
US7491748B2 (en) 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US7524969B2 (en) 2001-01-26 2009-04-28 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7723366B2 (en) 2001-02-20 2010-05-25 Chugai Seiyaku Kabushiki Kaisha Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases
US7786145B2 (en) 2003-08-01 2010-08-31 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
US7902354B2 (en) 2006-08-21 2011-03-08 Arqule, Inc. Lapachone compounds and methods of use thereof
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
CN102838515A (en) * 2011-06-23 2012-12-26 南京大学 Cinnamoyl sulfonamide compound preparation and applications of cinnamoyl sulfonamide compounds in anti-tumor treatment drugs
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8513027B2 (en) 1997-09-25 2013-08-20 Asterand Uk Acquisition Limited Method of identifying an inhibitor of the prostanoid EP4 receptor
US9675539B2 (en) 2000-03-31 2017-06-13 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
KR20170102885A (en) 2015-01-09 2017-09-12 오노 야꾸힝 고교 가부시키가이샤 Tricyclic spiro compound
CN107628981A (en) * 2017-10-31 2018-01-26 威海市妇女儿童医院 A kind of cinnamoyl sulfonylindoline compounds and its application for preparing glaucoma medicine
KR20190026736A (en) 2016-07-07 2019-03-13 오노 야꾸힝 고교 가부시키가이샤 Combinations consisting of an EP4 antagonist and an immuno checkpoint inhibitor
CN117164462A (en) * 2023-04-24 2023-12-05 江西师范大学 Diaryl methane compound and preparation method and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834224B2 (en) 1999-03-05 2011-12-14 デューク ユニバーシティ C16 unsaturated FP-selective prostaglandin analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (en) * 1979-09-05 1981-05-06 Glaxo Group Limited Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0157420A2 (en) * 1984-04-04 1985-10-09 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
US4996214A (en) * 1990-06-28 1991-02-26 Smithkline Beecham Corporation Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
EP0459243A2 (en) * 1990-05-30 1991-12-04 Bayer Ag Substituted Azines
WO1992002495A1 (en) * 1990-07-27 1992-02-20 Schering Aktiengesellschaft Berlin/Bergkamen Cyclopentane derivatives, process for producing them and their pharmaceutical use
EP0536713A1 (en) * 1991-10-07 1993-04-14 E.R. SQUIBB & SONS, INC. Oxazole and imidazole derivatives as prostaglandin analogs
EP0560080A1 (en) * 1992-03-03 1993-09-15 Hodogaya Chemical Co., Ltd. Electrophotographic toner
WO1996011902A1 (en) * 1994-10-12 1996-04-25 Zeneca Limited Pharmaceutically active substituted aromatic compounds
WO1996031505A1 (en) * 1995-04-07 1996-10-10 Pharmacopeia, Inc. Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997008934A2 (en) * 1995-06-19 1997-03-13 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1997010246A1 (en) * 1995-09-15 1997-03-20 Rhone-Poulenc Rorer S.A. INDENO[1,2-e]PYRAZIN-4-ONES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING SAME
WO1997025328A1 (en) * 1996-01-10 1997-07-17 Rhone-Poulenc Rorer S.A. 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF, INTERMEDIATES THEREOF AND DRUGS CONTAINING SAME

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2986262B2 (en) * 1991-09-18 1999-12-06 鐘紡株式会社 Whitening cosmetics

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (en) * 1979-09-05 1981-05-06 Glaxo Group Limited Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0157420A2 (en) * 1984-04-04 1985-10-09 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
EP0459243A2 (en) * 1990-05-30 1991-12-04 Bayer Ag Substituted Azines
US4996214A (en) * 1990-06-28 1991-02-26 Smithkline Beecham Corporation Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
WO1992002495A1 (en) * 1990-07-27 1992-02-20 Schering Aktiengesellschaft Berlin/Bergkamen Cyclopentane derivatives, process for producing them and their pharmaceutical use
EP0536713A1 (en) * 1991-10-07 1993-04-14 E.R. SQUIBB & SONS, INC. Oxazole and imidazole derivatives as prostaglandin analogs
EP0560080A1 (en) * 1992-03-03 1993-09-15 Hodogaya Chemical Co., Ltd. Electrophotographic toner
WO1996011902A1 (en) * 1994-10-12 1996-04-25 Zeneca Limited Pharmaceutically active substituted aromatic compounds
WO1996031505A1 (en) * 1995-04-07 1996-10-10 Pharmacopeia, Inc. Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997008934A2 (en) * 1995-06-19 1997-03-13 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1997010246A1 (en) * 1995-09-15 1997-03-20 Rhone-Poulenc Rorer S.A. INDENO[1,2-e]PYRAZIN-4-ONES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING SAME
WO1997025328A1 (en) * 1996-01-10 1997-07-17 Rhone-Poulenc Rorer S.A. 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF, INTERMEDIATES THEREOF AND DRUGS CONTAINING SAME

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 107, no. 21, 23 November 1987 (1987-11-23) Columbus, Ohio, US; abstract no. 190622c, GODA, YUKIHIRO ET AL.: "Inhibitors of the arachidonate cascade from Allium chinense and their effect on in vitro platelet aggregation" page 43; column 1; XP002900541 & CHEM. PHARM. BULL., vol. 35, no. 7, 1987, pages 2668-2674, *
CHEMICAL ABSTRACTS, vol. 109, no. 21, 21 November 1988 (1988-11-21) Columbus, Ohio, US; abstract no. 190191c, BUGGLE, K. ET AL.: "The reaction of diphenylsulfilimine with benzothiopyran-4-one 1,1-dioxides and benzothiopyran-2-ones" page 691; column 2; XP002900543 & J. CHEM. RES., SYNOP., no. 2, 1988, page 49 *
CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992 (1992-08-03) Columbus, Ohio, US; abstract no. 39800v, TSENG, CHENFANG ET AL.: "Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives" page 20; column 1; XP002900542 & CHEM. PHARM. BULL., vol. 40, no. 2, 1992, pages 396-400, *
CHEMICAL ABSTRACTS, vol. 119, no. 6, 9 August 1993 (1993-08-09) Columbus, Ohio, US; abstract no. 55727y, YOKOTA, TOMOHIRO: "Skin-lightening preparations containing cinnamic acid derivatives" page 423; column 2; XP002900538 & JP 05 078230 A (TOKKYO KOHO) 30 March 1993 (1993-03-30) *
CHEMICAL ABSTRACTS, vol. 91, no. 25, 17 December 1979 (1979-12-17) Columbus, Ohio, US; abstract no. 210985e, PLEVYAK, J.E. ET AL.: "Selective palladium-catalyzed vinylic substitutions with bromoiodo aromatics" page 644; column 1; XP002900540 & J. ORG. CHEM., vol. 44, no. 23, 1979, pages 4078-4080, *
CHEMICAL ABSTRACTS, vol. 95, no. 19, 9 November 1981 (1981-11-09) Columbus, Ohio, US; abstract no. 161760z, IIZUKA KINJI ET AL.: "Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives" page 25; column 1; XP002900539 & J. MED. CHEM., vol. 24, no. 10, 1981, pages 1139-1148, *
CHEMICAL ABSTRACTS, vol. 99, no. 15, 10 October 1983 (1983-10-10) Columbus, Ohio, US; abstract no. 115553u, ATKINSON, D.C. ET AL.: "Substituted (2-phenoxyphenyl)acetic acids with antiinflammatory activity" page 21; column 2; XP002900537 & J. MED. CHEM., vol. 26, no. 10, 1983, pages 1353-1360, *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513027B2 (en) 1997-09-25 2013-08-20 Asterand Uk Acquisition Limited Method of identifying an inhibitor of the prostanoid EP4 receptor
US9675539B2 (en) 2000-03-31 2017-06-13 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2001081312A2 (en) * 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
US6627656B2 (en) 2000-04-24 2003-09-30 Michel Gallant Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
WO2001081312A3 (en) * 2000-04-24 2002-08-08 Merck Frosst Canada Inc Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
WO2002002522A1 (en) * 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
WO2002018333A1 (en) * 2000-08-31 2002-03-07 Pfizer Limited Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
US6710054B2 (en) 2000-10-19 2004-03-23 Pfizer Inc Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
US7141580B2 (en) 2000-10-19 2006-11-28 Pfizer Inc. Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
US7479564B2 (en) 2000-10-19 2009-01-20 Raqualia Pharma Inc. Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
WO2002032900A3 (en) * 2000-10-19 2002-08-08 Pfizer Pharma Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
WO2002032422A3 (en) * 2000-10-19 2002-07-25 Pfizer Pharma Ep4 receptor inhibitors to treat rheumatoid arthritis
WO2002032900A2 (en) * 2000-10-19 2002-04-25 Pfizer Pharmaceuticals Inc. Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
WO2002032422A2 (en) * 2000-10-19 2002-04-25 Pfizer Pharmaceuticals Inc. Ep4 receptor inhibitors to treat rheumatoid arthritis
CN101967146B (en) * 2000-10-19 2015-04-08 拉夸里亚创药株式会社 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
EP1666480A1 (en) * 2000-10-19 2006-06-07 Pfizer Pharmaceuticals Inc. Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents.
US8119819B2 (en) 2001-01-26 2012-02-21 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7279477B2 (en) 2001-01-26 2007-10-09 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7385063B2 (en) 2001-01-26 2008-06-10 Chugai Seiyaku Kabushiki Kaisha Method for preparing imidazole derivatives
US7524969B2 (en) 2001-01-26 2009-04-28 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US8110686B2 (en) 2001-02-20 2012-02-07 Chugai Seiyaki Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7723366B2 (en) 2001-02-20 2010-05-25 Chugai Seiyaku Kabushiki Kaisha Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US7335776B2 (en) 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient
US7491748B2 (en) 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US7786161B2 (en) 2001-08-09 2010-08-31 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
WO2003024484A1 (en) * 2001-09-14 2003-03-27 Ono Pharmaceutical Co., Ltd. Remedies for pruritus
WO2003043655A1 (en) * 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
US6956050B2 (en) 2002-04-12 2005-10-18 Pfizer, Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US7001917B2 (en) 2002-04-12 2006-02-21 Warner Lambert Company Llc Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US8080665B2 (en) 2003-08-01 2011-12-20 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
US7285562B2 (en) 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
US7449482B2 (en) 2003-08-01 2008-11-11 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
US7786145B2 (en) 2003-08-01 2010-08-31 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
US7897615B2 (en) 2003-08-01 2011-03-01 Chugai Sciyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
WO2007018314A3 (en) * 2005-08-10 2007-07-05 Takeda Pharmaceutical Therapeutic agent for diabetes
WO2007018314A2 (en) * 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007027630A2 (en) * 2005-08-30 2007-03-08 Smithkline Beecham Corporation Genes associated with type ii diabetes mellitus
WO2007027630A3 (en) * 2005-08-30 2007-07-12 Smithkline Beecham Corp Genes associated with type ii diabetes mellitus
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
US8623903B2 (en) 2005-09-06 2014-01-07 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
US8039503B2 (en) 2006-08-21 2011-10-18 Arqule, Inc. Lapachone compounds and methods of use thereof
US7902354B2 (en) 2006-08-21 2011-03-08 Arqule, Inc. Lapachone compounds and methods of use thereof
WO2008099907A1 (en) 2007-02-16 2008-08-21 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
CN102838515A (en) * 2011-06-23 2012-12-26 南京大学 Cinnamoyl sulfonamide compound preparation and applications of cinnamoyl sulfonamide compounds in anti-tumor treatment drugs
KR20170102885A (en) 2015-01-09 2017-09-12 오노 야꾸힝 고교 가부시키가이샤 Tricyclic spiro compound
US10077247B2 (en) 2015-01-09 2018-09-18 Ono Pharmaceutical Co., Ltd. Tricyclic spiro compound
US10538502B2 (en) 2015-01-09 2020-01-21 Ono Pharmaceutical Co., Ltd. Tricyclic spiro compound
EP3778562A1 (en) 2015-01-09 2021-02-17 ONO Pharmaceutical Co., Ltd. Tricyclic spiro compound
US11192876B2 (en) 2015-01-09 2021-12-07 Ono Pharmaceutical Co., Ltd. Tricyclic spiro compound
KR20220038804A (en) 2015-01-09 2022-03-29 오노 야꾸힝 고교 가부시키가이샤 Tricyclic spiro compound
KR20190026736A (en) 2016-07-07 2019-03-13 오노 야꾸힝 고교 가부시키가이샤 Combinations consisting of an EP4 antagonist and an immuno checkpoint inhibitor
US11065226B2 (en) 2016-07-07 2021-07-20 Ono Pharmaceutical Co., Ltd. Combination comprising EP4 antagonist and immune checkpoint inhibitor
CN107628981A (en) * 2017-10-31 2018-01-26 威海市妇女儿童医院 A kind of cinnamoyl sulfonylindoline compounds and its application for preparing glaucoma medicine
CN117164462A (en) * 2023-04-24 2023-12-05 江西师范大学 Diaryl methane compound and preparation method and application thereof

Also Published As

Publication number Publication date
EP1071648A2 (en) 2001-01-31
WO1999047497A3 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
WO1999047497A2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6627656B2 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
US6242493B1 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US5521213A (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US6211197B1 (en) Prostaglandin receptor ligands
AU776831B2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
CA2017376C (en) Diarylstyrylquinoline diacids
AU2002350315B2 (en) Quinolinones as prostaglandin receptor ligands
AU772841B2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU756333B2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU752820B2 (en) Biphenylene lactams as prostaglandin receptor ligands
AU764872B2 (en) Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 27086/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2322742

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2322742

WWE Wipo information: entry into national phase

Ref document number: 1999907214

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999907214

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 27086/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999907214

Country of ref document: EP